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Abstract 
This thesis presents four research papers dealing with the metabolism of creatine 
and amino acids in the liver and pancreas. Creatine is synthesized in two enzymatic 
reactions that uti lize the amino acids arginine, glycine and methionine. The first step in 
creatine synthesis is the transfer of the amidino group of arginine onto the amine of 
glycine resulting in ornithine and guanidinoacetate, catalyzed by the enzyme 
arginine:glycine amidinotransferase. The guanidinoacetate can then be methylated by the 
universal methyl donor S-adenosylmethionine to fonn creatine and S-
adenosylhomocysteine. The first two papers investigate the role of the rat liver and 
pancreas in creatine biosynthesis respectively, using both in vivo and in vitro techniques. 
I provide evidence that the liver does not perfonn the first step of creatine synthesis but 
does perfonn the second step and has the capacity to methylate all of the 
guanidinoacetate that is synthesized in the kidney. The third paper examines the effects of 
creatine-supplementation in high-fat diet fed rat model of non-alcoholic fatty liver 
disease. This paper shows that dietary creatine-supplementation prevents the 
accumulation of lipids in the livers of rats fed high-fat diets as well as a number of the 
negative observations associated with non-alcoholic fatty liver disease. The fourth paper 
deals with the fate of perivenous hepatocytes in rats that have undergone portacaval 
shunts. It is known that the expression of hepatic glutamine synthetase is markedly down-
regulated in portacaval anastomosis and it has been suggested that there is a loss of the 
perivenous hepatocytes which contain this enzyme activity. I provide evidence that 
omithine aminotransferase activity and the expression of an ammonium transporter 
RhBG, proteins known to be localized in the perivenous cell population, are increased 
and unchanged respectively in rats with portacaval anastomosis. The papers presented in 
this thesis a) show the major role of the liver in creatine synthesis, b) demonstrate a 
possible role for the pancreas in creatine synthesis, c) introduce creatine as a potential 
treatment for fatty liver disease, and d) demonstrate that perivenous hepatocytes are not 
lost during portacaval shunting. These constitute important contributions to the current 
body of literature relating to creatine metabolism and hepatic zonation. 
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Chapter 1 
General Introduction 
1.1.1 A Brief History ofHepatology 
The liver is one of the first and largest organs that can be seen upon opening the 
abdomen of a mammal and its distinct appearance can change dramatically as a result of 
alterations in physiology. It is likely that the physical attributes of the liver and those 
changes related to pathological situations led cultures throughout antiquity to use the liver 
as a tool for mystical and religious explanations of various phenomena. Ancient cultures 
such as the Babylonians, Assyrians and Etruscans believed that the future could be 
foretold by examining the livers of sacrificial animals (52). Many of these cultures 
consulted a mystic who used the excised liver of an animal (sometimes human) to foretell 
the outcomes of coming battles; history is littered with numerous depictions of this 
custom. There is also the famous Greek legend of the Titan, Prometheus, who stole fire 
from Zeus and gave it to humankind. As a punishment Zeus tied Prometheus to a rock 
where a great eagle came daily to feast on his liver only to have it grow back for the next 
day's feast. This story could very well have been crafted through some experience with 
liver regeneration, another striking attribute of the liver. And so the liver has been revered 
and celebrated by humankind throughout the ages. The basic, gross fundamental 
attributes of the liver have been identified and used as evidence to rationalize and explain 
historic events. At present we know many of the finer details related to the crude historic 
descriptions of the liver, but it is the prominence and early recognition of this organ that 
has dri ven philosophers and scientists to ask questions about how the liver works. 
Perhaps the most notable early studies on animal physiology were carried out in 
Greece by Galen of Pergamum 129-199 AD. It was generally accepted in the time of 
Galen that the liver was responsible for turning digested food into blood, and that the 
liver was the origin of all of the veins (125). While we now know this to be inaccurate it 
is not hard to understand the ideas of the time. The liver does contain a great deal of 
blood (to which it owes most of its red /brown color) and considering the visible 
vasculature and position (central and above all other organs in the peritoneal cavity) of 
the liver these conclusions are understandable. These ancient Greek ideas were held by 
medical practitioners for centuries and it was not unti l the 15th century when Paracelsus 
began to challenge old ideas and introduced the idea that the liver was separating food 
chemically and not "digesting" the food itself ( 125). Some time after Paracelsus the 
famous Italian physician Andreas Vesalius 15 14-1564 AD published his work De 
Humani Corporis Fabrica (On the Material of the Human Body). Within this body of 
work there is an intricate diagram and detailed description of the anatomy of the digestive 
tract and greater insight into the function of the liver. Even though Vesalius maintained 
many of the older Galenic ideas about nutrition he was able to identify the vasculature of 
the liver and had the correct notion that nutrients travel from the intestines to the liver, as 
seen in the description he gives in his Epitome ( 167): 
"The veins suck out from the intestines (especially the small ones) whatever is 
suitable for the making of blood, together with the aqueous and thin refuse of the 
stomach's concoction, and carry it to the workshop of the liver, where the blood is 
made .... It is the tinder of the natural or nutritive faculty or, as Plato said, of the part of 
the soul which desires the pleasures of love, food, and drink." 
-Andreas Vesalius 
Exactly how the machinery of the liver works would not be discovered until much 
later and it was not until the relatively recent discovery and characterization of enzymes 
that the full role of the liver would be clear. The discovery and characterization of the 
urea cycle and its catalytic mechanism for the removal of nitrogen in the liver by Hans 
Krebs is profoundly important in our current understanding of the liver. We now know 
that the liver has a unique vasculature and is responsible for the metabolism of all the 
macronutrients and many of the micronutrients. It is with a similar fascination to that 
shared by people throughout the ages that I began, and indeed, continue my study of how 
the human body works. It is the goal of this thesis to describe some aspects of hepatic 
metabolism with a particular focus on the metabolism of creatine and the amino acids. I 
will introduce creatine metabolism and hepatic zonation and then present three research 
papers that address some questions that have arisen regarding liver creatine and amino 
acid metabolism. 
1. 1.2 Scope of Thesis 
This thesis deals mainly with creatine metabolism in the liver and pancreas. In 
addition it addresses a question regarding hepatic zonation in the li ver. The first paper 
examines the methylation of GAA in rat liver and the effect of methionine thereon. The 
possibility of de novo creatine synthesis from arginine derived from the urea cycle and 
recycling of the ornithine formed to arginine in the liver is also tested. The second paper 
deals with the role of the pancreas in total body creatine synthesis in the rat. The third 
paper examines the effects of dietary creatine supplementation in preventing non-
alchoholic fatty liver disease (NAFLD). 
Finally, the fourth paper deals with the fate of perivenous hepatocytes in rats that have 
undergone portacaval anastomosis as a model for the condition of liver cirrhosis. The 
author appreciated that the study conducted in the following chapter is not directly related 
to the topics addressed in the three preceding chapters. Nevertheless, it is intimately 
related to the field of hepatic amino acid metabolism which encompasses the creatine 
studies. In fact chapter 5 represents the first study undertaken during my PhD research. 
However, the focus of the laboratory changed to creatine due to grant funding exigencies. 
For this reason the remaining studies dealt with creatine metabolism. 
1.1.3 Overview of Liver Anatomy and Metabolism 
In this section I will briefly address some of the metabolic functions of the liver 
and some anatomical features that are relevant to the work that I will present. The liver 
sits high within the peritoneal space in the abdomen, very close to the stomach, pancreas 
and intestines. It has an unusual vasculature being fed by both arterial and portal venous 
blood (Figure 1.1 ). The hepatic artery carries arterial blood; however this only accounts 
for approximately 25% of total hepatic blood flow (52). The remaining 75% of blood 
flow is supplied by the hepatic portal vein which carries venous blood from splanchnic 
organs including the pancreas, stomach, spleen and intestine. The portal blood is 
somewhat lower in oxygen content than is arterial blood but contains a much larger 
concentration of nutrients and hormones. In addition, the liver secretes bile which is 
stored in the gall bladder (except in some species, notably the rat where bile is secreted 
directly into the intestine) which in tum transfers the bile to the intestine providing bile 
acids, phospholipids and cholesterol that assist in the digestion of fat. 
Figure 1.1 
Hepatic blood flow. Direction of blood flow is denoted by arrows and symbols are 
defined as follows: Hepatic Artery (HA), Portal Vein (PV) and Hepatic Vein (HV). 
Original art. 

The liver perfonns numerous, varied and sometimes opposing metabolic 
processes. These are often facilitated by a unique micro-structural organization that adds 
a level of complexity to hepatic metabolism (132). Liver cells are grouped into small 
roughly hexagonal units called acini: coming from the Latin word 'acinus' meaning 
"berry' (Figure 1.2 and 1.3). The acinus represents the smallest functional unit of the 
liver above the level of the cell. Both the hepatic portal venous blood and arterial blood 
feed into the acinus and this blood collects in the central vein after it transits the acinus. 
As the blood flows along the acinus the contents of the blood change based on what 
molecules are being taken up and released by the cells (Figure 1.3). As a result the cells 
that occupy different positions in relation to the blood flow take on different roles and 
this phenomenon is called hepatic zonation. The separation of metabolic processes plays 
a crucial role in the regulation of metabolism. 
1.1.4 Creatine Metabolism 
Creatine is perhaps most widely known as a popular sports supplement taken by 
athletes and bodybuilders. The role that creatine plays in improving muscle perfonnance 
is most significant for very short (seconds) bursts of power that consume a large amount 
of ATP such as resistance exercises (133, 169). In the presence of ATP, creatine can be 
converted to creatine phosphate through the action of the enzyme creatine kinase which 
catalyzes the reaction shown in equation I below. 
Figure 1.2 
Cross-section of li v_er acini: blood fl ows from the portal triad across the aci nus and 
collects in the central vein. Arrow indicates direction of blood flow. Metabol ic zones: 
zone I (periportal), zone 2 (intem1ediate), zone 3 (perivenous). Adapted from Kuntz; 
Hepato logy 2008 (52). 
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Figure 1.3 
Diagram of proposed hepatic zonation of metabolism. Taken from (27). 
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Equation I: (\ 
Physiologically, this reaction is reversible and the substrates creatine phosphate, ATP, 
creatine and ADP are held in equilibrium. There are four known isofonns of creatine 
kinase: brain (bCK), muscle {mCK), ubiquitous mitochondrial (UmiCK) and sarcomeric 
mitochondrial creatine kinase (SmiCK) (176). At the cellular level, bCK and mCK are 
localized in the cytosol while miCK is found in the mitochondria of cells that have the 
full creatine kinase "high energy" phosphate shuttle. Mitochondrial creatine kinase 
nonnally exists as an octamer and is found in heart, brain, muscle, retina, and spenn~ the 
sarcomeric enzyme is found mainly in the muscle (89). The brain and muscle isofonns of 
creatine kinase are expressed in their respective tissues where they fonn functional 
dimers. The heart is the notable exception which expresses both the brain and muscle 
isofonns, which fonn a mixed dimer of the enzyme. The creatine, creatine phosphate 
system is most active in fast-twitch muscle, heart and brain but is also active in the other 
tissues that express mitochondrial creatine kinase (1 86). The creatine, creatine phosphate 
system buffers ATP in a spatial as well as a temporal fashion. The concentration of 
creatine phosphate along with the presence of cytosolic creatine kinase enzyme near sites 
of A TP utilization allows for the quick regeneration of A TP at the expense of creatine 
phosphate while the localization of mitochondrial creatine kinase at the site of A TP 
generation allows for the synthesis of creatine phosphate and regeneration of ADP. Thus 
creatine acts as a carrier of "high-energy" phosphate groups between locations of 
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utilization and generation within cells buffering ATP in a spatial fashion. Some 
advantages of this phenomenon are that the diffusion rates of creatine phosphate and 
creatine are much higher than those of ATP and ADP (82, 191) making their transfer 
through aqueous cytosol faster. The higher concentrations of creatine and creatine 
phosphate increase the 'effective' ATP concentration without increasing the actual ATP 
concentration, the consequence of which would affect enzymes that use A TP as a 
substrate or allosteric regulator. 
1.1.5 Creatine Biosynthesis 
Creatine was first isolated in the 1830's by Michel-Eugene Chevreul from muscle 
extracts and named after the Greek word ''Kreas" meaning ' flesh'. Creatine is a naturally 
occurring, endogenously synthesized metabolite found in most vertebrates ( 163). 
Creatine is found in the highest concentrations in tissues that have high activities of 
creatine kinase such as the muscle and brain. Creatine is not known to be metabolized 
enzymatically in mammals other than by conversion to creatine phosphate by creatine 
kinase, but creatine and creatine phosphate spontaneously cyclize to fonn creatinine 
which is eventually excreted in the urine at a rate of about 2 percent of total creatine per 
day (186). Therefore since total body creatine is relatively constant in adults, the lost 
creatine must be replaced either by dietary intake or by de novo biosynthesis. Major 
dietary sources of creatine arc meat and dairy products. 
Creatine arises from the metabolism of the amino acids arginine, glycine and 
methionine and its synthesis involves only two enzymes (Figure 1-4). The first step of 
creatine synthesis requires the enzyme arginine:glycine amidinotransferase which 
catalyzes the transfer of the guanidino group of an arginine molecule onto the amine of a 
14 
glycine molecule, yielding ornithine and guanidinoacetate. The second enzyme is 
guanidinoacetatc N-methyltransferase which catalyzes the transfer of the methyl group 
from S-adenosylmethionine (SAM), resulting in a molecule of creatine and S-
adenosylhomocysteine (SAH). The process of creatine synthesis is largely an inter-organ 
pathway involving mainly the kidney and liver. The enzymes of creatine biosynthesis are 
located in various tissues and are expressed at varying levels. AGA T is located primarily 
in the pancreas and kidney; however, some activity has been reported in the heart, lung, 
spleen, muscle, brain, testis and thymus (1 63). There have also been reports of AGAT 
activity detected in the livers of cow, pig, monkey and human, meaning that the complete 
synthesis of creatine might be occurring in this tissue. However there are difficulties with 
the traditional assay for AGAT in liver due to interference by omithine produced by the 
arginase enzyn1e (186). GAMT is perhaps more widely expressed but the highest 
activities are present in the pancreas and liver with lower expression in a much broader 
range of tissues ( 163). 
15 
Figure 1.4 
Creatine Biosynthesis. AGAT; Arginine:glycine amidinotransferase, GAMT; 
Guanidinoacctate N-methyltransferase. 
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The primary re~;,rulation of creatine synthesis occurs in the kidney. There is a 
feedback regulation by creatine on the expression of AGA T in the kidney at the pre· 
translational level ( 113). Growth honnone also affects the expression of renal AGA T as 
described in an elegant study by McGuire et a!. (114) using hypophysectomized rats. 
Apart from the regulatory effect of growth honnone and creatine on creatine synthesis the 
concentration of the substrates for GAMT and AGA T can also affect creatine synthesis. 
Like the other methyltransferase enzymes, the velocity of GAMT is influenced by the 
concentrations of SAM and SAH; GAMT activity increases in the presence of higher 
SAM concentration and decreases in the presence of higher SAH concentration (37). 
Therefore changes in the concentration of SAM or SAH will have an effect on the rate of 
methylation ofGAA. Finally, renal infusion studies by Edison ct al. (49) have shown that 
infusion of arginine significantly increases the production ofGAA in the kidney. 
1.1.5.1 Argininc:glycinc Amidinotransfcrasc 
Arginine:glycine amidinotransferase occurs as an 84 kOa dimer and is located in 
the mitochondria. It is translated on cytoplasmic ribosomes and is translocated into the 
mitochondria with the cleavage of a 3 kDa section of the protein, resulting in the most 
active fonn of the enzyme (112). The protein structure contains five ppap sections which 
are arranged in a 'basket' shape with alpha helices fom1ing the sides and beta sheets 
fom1ing the base (73). The active site involves coordination of helix 9 and a loop called 
the "3QQ.loop" for binding of the substrates. The mechanism of AGA T is a ping· pong 
type reaction involving initial binding of arginine, transfer of the amidino group onto the 
enzyn1e, release of ornithine, fo llowed by the binding of glycine and subsequent transfer 
of the amidino group onto the amine group of glycine. The AGAT protein sequence has 
18 
been detennined and there is a conserved cysteine residue in the active site of the AGAT 
protein which fonns isothiourea in the process of transferring the amidino group (74). 
Physiologically the AGA T enzyme runs in favor of guanidinoacetate fonnation 
and is inhibited by ornithine. Some older studies have shown that the enzyme can indeed 
run in the reverse direction fanning glycine and arginine (139). This is supported in 
studies by Walker using radioactive 2-14C-omithinc (171 ) and 2-14C-glycine as substrates 
for purified AGAT enzyme (174). It was found that radioactivity was present in arginine 
and guanidinoacetate. The Km for glycine, arginine, guanidinoacetate and ornithine have 
been detennined in vitro to be 1.8-3. 1, 1.3-2.8, 3.9 and 0.1 mM respectively (186). This 
would suggest that AGAT is responsive to relatively lower amounts of ornithine than any 
of the other potential substrates. The question of whether the reverse reaction occurs 
under differing physiological situations or in vivo is unanswered. Other substrates may 
also be used in certain physiological situations. For instance, the compound canavanine 
(Fi1:,rure 1.5), which is the guanidinoxy analogue of arginine is found in a number of 
legumes including alfal fa and jack beans, and is a known substrate of AGAT (1 72) and 
arginase (40). Thus if canavanine is present in the diet it might very well serve as a 
substrate for the AGA T enzyme. 
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Figure 1.5 
Structures of Guanidinoacctate, Arginine and Canavanine. The oxygen in Canavanine is 
bolded to illustrate the difference between the guanidine and guanidinoxy compounds. 
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1.1.5.2 Guanidinoacetate Methyltransferase 
GAMT is a member of the large family of methyltransferases responsible for the 
irreversible transfer of the methyl group of SAM onto an amine. Rat liver GAMT was 
first purified by Ogawa et al. in 1983; it was detennined to have a molecular weight of 26 
kDa and a sulphydryl character that was integral for activity (I 26). Later GAMT was 
shown to have 4 cysteine residues, one of which was located in the active site (57) and 
the catalytic mechanism was detennined after the crystal structure was elucidated (93). 
GAMT adopts the alP sandwich structure common to all SAM dependent 
methyltransferases, binding SAM and GAA in appropriate proximity for reaction. The 
reaction is irreversible and is not inhibited by the presence of excess creatine (up to about 
5 mM) or any creatine analogues (57). GAMT seems not to be acutely regulated nor docs 
it appear to be regulated by dietary creatine, at least in the liver, and therefore GAMT 
appears to be a slave to the concentration of GAA that it encounters. There seem to be no 
accounts of GAMT regulation and only a few accounts of its activity in the pancreas (23, 
163). Activity of GAMT in the pancreas is high and even though the tissue is small, it 
may have an impact on total body creatine synthesis. The second paper attempts to 
address the question of whether dietary creatine has a regulatory effect on GAMT 
expression in the pancreas and whether the pancreas can indeed produce creatine de novo. 
1.1.5.3 Creatine T ransport into Cells 
Creatine transport is well described in the tissues that use the creatine kinase system such 
as the muscle and brain. The creatine transporter, SLC6A8, has been shown to have a 
higher affinity for creatine than for any other guanidine compounds, it is sodium-
dependent and is capable of concentrating creatine as high as I 00 fold within cells 
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relative to plasma concentration (64). Expression of SLC6A8 correlates well with the 
creatine content of tissues as well as the expression of creatine kinase, with the notable 
exception of the kidneys which have a much higher creatine transporter content and very 
little creatine kinase activity (186). The funct ion of the SLC6A8 in the kidneys is to 
reabsorb creatine, as the urine contains very little of this molecule. There have been 
reports of the creatine transporter protein in mitochondria of liver and kidney (178) but 
these experiments were carried out using an antibody now known not to be specific; in 
particular it cross-reacts with the E2 subunit of pyruvate dehydrogenase (151). The 
SLC6A8 transporter is not found at high levels in any of the tissues known to synthesize 
creatine; however there must be some mechanism, whether passive or active, that 
transports creatine out of these tissues. 
1.1 .6 Creatine Deficiency 
Creatine deficiency was fi rst described in 1994 by Stockier et al. ( 155) and was 
later characterized as a deficiency of the GAMT enzyme ( 156). Since then, deficiencies 
of both enzymes of creatine synthesis as well as the sodium-dependent creatine 
transporter have been characterized (144). Creatine deficiency syndromes are apparent in 
very young individuals and interestingly, all of these syndromes show symptoms of 
neurological impainnent, perhaps emphasizing the importance of creatine for nonnal 
development and funct ion of the brain. The features of creatine deficiency syndromes are 
presented in a condensed fonn in Table 1-1. 
AGAT and GAMT deficiencies present with similar symptoms (Table 1-1). 
GAMT deficiency displays slightly more severe neurological dysfunction, usually 
attributed to the neurotoxic properties of GAA ( 118). Inheritance of GAMT deficiency is 
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autosomal recessive. Reports of this deficiency are relatively recent and thus the number 
of cases is low but increasing as more research is completed (46). GAMT deficiency 
results in elevated guanidinoacetate (GAA) and decreased levels of creatine in plasma 
and in some other tissues. Mutations in the gamt sequence have been identified (5, 75) 
and include deletions and point mutations affecting the active site either directly or 
indirectly, by changing the structure of the active site itself or the N-tenninal section of 
the protein. 
AGAT deficiency was first reported in 2000 by Bianchi et al. (1 7) and shortly 
thereafter, it was characterized as a transition mutation resulting in a premature stop 
codon in the agat gene (76). At present, there are only three families with children who 
have been found to be deficient in AGAT (50) and all have different mutations. AGAT 
deficient subjects have only trace amounts of guanidinoacetate in their tissues and almost 
no creatine. Deficiency in the SLC6A8 protein is different from the other two creatine 
deficiency syndromes in that patients do not have a total lack of creatine; in fact, they 
have nonnal or elevated plasma and CSF creatine, but are not able to transport creatine 
into the muscle and brain (22). There is some evidence that creatine transporter 
deficiency may have a relatively high frequency of occurrence. One study found that 
approximately 2% of males with undiagnosed developmental delay were creatine 
transporter-deficient ( 123). 
Diagnosis of the creatine deficiency syndromes is accomplished by 31 P NMR 
(MRS) in the brain and muscle, detennination of plasma GAA and creatine 
concentrations and enzyme activities in cultured fibroblasts. Both AGA T and GAMT 
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Table I- I 
Clinical and biochemica l characteri stics of GAMT, AGA T, CRTR deficiency and 
d iagnostic tests. ( I 59) 
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Table 1. Clinical and bioche mical characteristics of GAMT, AGAT and CRTR d eficiency and diag-
nos ti c tests 
Disorder Clinical Biochemical cha ra cteristics Diagnostic test Confirmation 
characteristics 
GAMT Mental retardation Deficiency of brain creatine Brain MRS GAMT activity 
(f,l) 
Speech delay Accumulation of guac Guac u, p, csf. dbs 
Epilepsy Low creatinine and Creatinine 24 h w·ine GAMT (intractable) creatine excretion Creatine & creatinine mutations 
in csF· (b,f,l,dbs) (Extra) pyramidal High urinary uric acid/ Creatine, creatlnine. 
symptoms & signs creatinine ratio uric acid in urine 
AGAT Mental retardation Deficiency of brain creatine Brain MRS AGAT activity 
Low guac excretion Guac u, p, csf. dbs (f,l) 
Speech delay Low creatine excretion ? Creatine urine AGAT muta-
Low creatinine Creatinine 24 h urine tions 
(Epilepsy) excretion ? (b,f,l,dbs) 
CRTR Mental retardation Deficiency of brain creatine Brain MRS CRTR acth·ity 
(f,l) 
Speech delay Low creatinine Creatin ine 24 h urine CRTR mutation 
excretion ? (b.f.l) Epilepsy High urinary creatine/ Creatine and 
creatinine ratio creatinine urine 
Abbrevations: Guac, guanidinoucetate: u, m·ine; p, plasma: csf, cerebrospinal fluid; dbs, dry blood spot sample; f, 
fibroblasts; I, lymphoblasls: b, blood;?, expected but not measured so fur in respective pntient.s. •StOckier ct a/ .. 1997: 
Schulze eta/., 1997. 
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deficiency have been successfully treated with creatine supplementation between 350· 
2000 mglkglday and it appears that earl ier intervention leads to a better prognosis (144). 
Treatment of SLC6A8 deficient subjects with oral creatine has not been reported to be 
beneficial (I 02). 
1.1. 7 C reatine in the Brain 
The creatine deficiency syndromes highlight the importance of creatine in the 
brain. Creatine in the brain is about one·third of the creatine concentration found in 
muscle. The firing of a neuron relies on sodium inflow to collapse its concentration 
gradient. This gradient is subsequently re-fonned and maintained within the cells by 
sodium:potassium ATPase and so demands large, acute energy consumption for which 
creatine phosphate is integral. The creatine kinase system supports many of the ion 
transporting A TPase proteins by maintaining the concentration of A TP ncar the 
functioning proteins (177). But creatine may serve an additional role in the brain. There 
has been a large scale clinical trial launched by the National Institutes of Health {NIH) to 
find compounds that may be used as a treatment for Parkinson's disease and creatine has 
been included as a candidate (38). Parkinson's disease is caused by a gradual loss of 
dopamincrgic neurons mainly in the substantia nigra which leads to movement disorders 
( I 85). Creatine is reported to be neuroprotective, preventing mitochondrial dysfunction 
and oxidative damage and is believed to be therapeutic in a range of brain disorders (3). 
1.1.8 Methionine and Creatine metabolism 
Methionine is one of two sulfur-containing amino acids that can be incorporated into 
proteins. Aside from its role in protein synthesis, methionine is the precursor for the 
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universal methyl donor SAM. A detai led diagram of methionine metabolism is given in 
Figure 1.6. SAM is the substrate used by a family of methyl transferase proteins including 
glycine-N-methyltransferase (GNMT), guanidinoacetate metl1yltransferase GAMT, 
phosphatidylethanolamine methyltransferase (PEMT), DNA methyltransferase (DNMT) 
and others. Biological methyltransferases are mainly regulated by the concentrations of 
SAM and SAH; a higher SAM/SAH ratio results in an increased rate of methylation and 
vice versa (37). The availability of SAM in the liver seems to be partially mediated by the 
most active methyltransferase, GNMT (1 19). The regulation of many biological 
methylation reactions also relies in part on the availability of methyl-accepting substrates 
as outlined by the Stead et al. (26, 152) who introduced the tenn 'methylation demand'. In 
addition, a few methylation reactions arc compartmentalized within cells and use 
different SAM/SAH pools, adding a layer of complexity. Two examples of this are 
PEMT which is located in the ER (148), and DNMT in the nucleus (109). Pools of 
tetrahydrofolate are also compartmentalized ( I 08), affecting the regeneration of 
methionine from homocysteine and thus affecting the respective pool of SAM. 
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Figure 1.6 
Methionine metaboli sm. Symbols are defined as follows: MAT; Methionine 
adenosyl transferase, GNMT; Glycine N-methyltransferase, SAHH ; S-
adenosylhomocysteine hydrolase, BHMT; Betaine :homocysteine meth yltransferase, MS; 
Methionine synthase, SHMT; Serine hydroxymethyltransferase, MTH FR; 
Meth yltenetrah ydrofolate reductase, C{JS ; Cystathionine {3-synthase and Cy L; 
Cystathionine y-lyase. 
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For every molecule of creatine that is synthesized, one equivalent methyl group is 
required. It was originally calculated that creatine synthesis was responsible for 
consuming 70-75% of the labile methyl groups that are metabolized per day ( 120, 187). 
However more recently this number has been revised to give a value of 40% of methyl 
groups being used for synthesis of creatine, still a considerable portion (153). Thus, 
creatine biosynthesis is a major consumer of methyl groups. 
1.1.9 Non-Alcoholic Fatty Liver Disease 
Non-Alcoholic Fatty Liver Disease (NAFLD) is the tenn used to describe a 
number of conditions (not related to alcohol consumption) that lead to fibrosis and can 
progress to full blown liver cirrhosis. Fatty liver has been associated with obesity and 
decreased insulin sensitivity, and is considered the hepatic manifestation of the metabolic 
syndrome (47). The hallmark of NAFLD is the accumulation of triglycerides in lipid 
droplets within hepatocytes, often accompanied by inflammation referred to as non-
alcoholic steatohepatitis (NASH). A "two-hit" model has been proposed; the first hit is 
infiltration of fat into hepatocytes increasing sensitivity to the second hit which can 
include oxidative stress, lipid peroxidation, pro-inflammatory cytokine-mediated cell 
injury and cell death (6). The pathogenesis of NAFLD is not yet clear. The disorder can 
arise from three general situations I) excessive influx of fatty acids that have been 
released from adipose tissue or from digestion, 2) diminished hepatic export of TG 
(increased VLDL synthesis/decreased export), 3) impaired beta oxidation, each of which 
can result from overfeeding, obesity, drugs that inhibit microsomal triglyceride transfer 
protein (MTP), methionine/choline deficiency, some vitamin deficiencies and some 
genetic disorders (95). 
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Several different animal models have been generated in order to study NAFLD; 
these different models display varying degrees of inflammation, fibrosis and metabolic 
syndrome. Mice with knock-outs of either fatty acyl-CoA oxidase, methionine 
adenosyltransferase, SREBP-1 c, PEMT, PPARa, leptin/leptin receptor or pten all develop 
steatosis but none shows the full spectrum of NAFLD and only a few show signs of 
steatohepatitis. Dietary models include methionine-choline deficient, arginine deficient, 
atherogenic, high-fructose/high-sucrose, and high fat diets (6, 101, Il l). From the 
literature, the animal models that display the most simi larity to NAFLD are the PEMT, 
SREBP- lc, leptinlleptin receptor knock-outs and the atherogenic, methionine-choline 
deficient and high fat diets. These models all progress to NASH and fibrosis. 
1.1.10 Phosphatidylcho\jne and the Role of Methylation in Lipid Metabolism 
Phosphatidylcholine (lecithin) is integral to the structure of biological membranes, 
the packaging and transport of lipids and the enterohepatic circulation of bile acids. 
Phosphatidylcholine represents more than 90% of the phospholipids found in mucus and 
has been used successfully as a therapy in patients with ulcerative colitis ( 158). 
Phosphatidylcholine is one of the major phospholipids found in membranes and 
lipoproteins, together with phosphatidylethanolamine and phosphatidylscrine. The 
various properties and proportions of the phosphol ipids can affect the behavior of 
membranes as well as the proteins functioning within and proximal to the membrane. In 
addition to its structural functions, phosphatidylcholine is a substrate for other enzyn1es 
such as phospholipases and lecithin: cholesterol acyltransferase, fom1ing other important 
molecules such as sphingomyelin, lysophosphatidylcholine and cholesterol esters. 
Phophatidylcholine can be catabolized, through a number of steps, to choline and 
32 
glycerol-3-phosphate and choline itself can be metabolized further into betaine which is 
used to rcmethylate homocysteine (Figure I. 7). Choline is considered an essential 
nutrient; an adequate intake for adolescent and adult humans is between 400 and 500 
mgt day ( 140). 
Phosphatidylcholine itself is synthesized in the liver by two separate pathways. In 
the Kennedy pathway, choline kinase converts a molecule of choline to phosphocholine 
which phosphocholine cytidylyltransferase converts to cytidine diphosphocholine. 
Diacylglycerol cholinephosphotransferase transfers the phosphocholine group to a 
molecule of I ,2-diacylglycerol ( I 05) (Figure ! .Sa). The second pathway involves three 
successive methylations of the nitrogen of phosphatidylethanolamine, resulting in a 
molecule of phosphatidylcholine, catalyzed by PEMT (Figure 1.8b). In rats, 
approximately 70% of de novo phosphatidylcholine is derived from the Kennedy 
pathway leaving PEMT to synthesize the remaining 30% (134). The requirement of three 
methyl groups for every one molecule of phosphatidylcholine synthesized means that 
even the synthesis of a relatively small amount of this molecule could have a significant 
impact on methylation. PEMT knock-out mice fed a nonnal chow diet had 50% less 
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Figur-e 1.7 
Phosphatidylcholine catabol ism. 
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plasma homocysteine than control mice and isolated liver cells from these animals 
secreted 50% less homocysteine than cells from control mice (124). This suggests that 
even under nonnal conditions PEMT places a heavy demand on the provision of methyl 
groups. Phosphatidylcholine synthesis seems to be important in hepatic steatosis as 
steatosis may be brought about by feeding diets deficient in methionine and choline. In 
addition, another methyl donor, betaine, alleviates symptoms of the closely related 
alcohol-induced steatohepatitis in mice (87). Thus the main hypothesis of the third paper 
is that sparing methyl groups by reducing the need for creatine synthesis in the liver 
would provide more methyl groups for phosphatidylcholine synthesis and hence provide 
more phosphatidylcholine for VLDL synthesis, thus alleviating fatty li ver. 
1.2.0 Portacaval Anastomosis 
Portacaval anastomosis (also tenned ' portacaval shunt' ) is the diversion of blood 
flow from the hepatic portal vein away from the liver into the systemic circulation. This 
phenomenon can arise when there is portal hypertension, such as during conditions of 
portal thrombosis, chronic fatty liver, liver cirrhosis or another physical blockage (i.e. 
surgical procedure) (97). In these situations collateral vessels can carry portal blood 
directly to the hepatic vein. In addition, portacaval anastomosis is a routine surgical 
treatment for chronic portal hypertension. The physiological impact of portacaval 
anastomosis is significant. The blood that collects in the portal vein feeding the liver is 
very different from other venous and arterial blood, as discussed in section 1.1.3. There 
are higher concentrations of amino acids and ammonia present in plasma after digestion 
of a meal in humans with transjugular intrahepatic portosystemic shunt (TIPS) (1 30) (a 
slightly different means of bypassing the liver). The concentration of ammonia in the 
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plasma is higher in rats with portacaval anastomosis fed a high protein diet versus a 
nonnal protein diet (1 3). Hepatic encephalopathy may result from hypcrammoncmia and 
changes in the levels of plasma amino acids after portacaval anastomosis (52, 54). 
1.2.11:1ctcrogeneity of Liver Nitrogen Metabolism 
Liver cells that span the acinus have different metabolic functions. The periportal 
cells arc mostly responsible for net gluconeogenesis, fatty acid oxidation, urcagcnesis and 
albumin synthesis while the perivenous cells arc responsible for net glycolysis, fatty acid 
synthesis, glutamine synthesis and xcnobiotic metabolism ( 13 1 ). In addition the majority 
of blood that flows into the liver has passed through the intestine so that its composition 
will reflect absorptive processes and intestinal metabolism. The liver is largely 
responsible for the oxidation and metabolism of most amino acids and so too it must deal 
with the free ammonia resulting from this metabolism. The liver has two ways of dealing 
with free ammonia; I) the urea cycle and 2) glutamine synthesis. The urea cycle catalyzes 
the synthesis of urea; this metabolic end-product is excreted in the urine. Glutamine 
synthetase uses ammonia as a substrate in synthesis of the amino acid glutamine so that 
toxic levels of ammonia do not accumulate. The urea cycle is a low affinity, high 
capacity system and works best under relatively high concentrations of ammonia while 
glutamine synthetase is a high affinity, low capacity enzyme (84). The two processes are 
localized to different cell populations across the acini of the liver (Figure 1.3). The urea 
cycle enzyn1cs arc active in the periportal hepatocytes while glutamine synthetase is 
active in the last 2 layers of perivenous hepatocytes (83). In general, it is thought that the 
urea cycle deals with the bulk of ammonia leaving glutamine synthetase to 'scavenge ' the 
slight excess ammonia that has 'escaped '. 
39 
The liver contains both glutaminase and glutamine synthetase activities. The 
balance of glutamine across the liver, however, is often close to zero (179). Glutamine is 
catabolized in periportal cells by glutaminase and glutamate dehydrogenase to form a-
ketoglutarate and two ammonia molecules. Alternatively, the combination of glutaminase 
and aspartate aminotransferase can produce aspartate and ammonia which are directly 
used in the urea cycle ( 11 5). There are two isofonns of phosphate dependent glutaminase: 
I) kidney-type and 2) liver-type. The kidney-type glutaminase is found in extra-hepatic 
tissues such as the kidney, brain and cells of the immune system (36). The kidney-type 
glutaminase, like the liver isofonn is found in mitochondria but has a much lower Km for 
glutamine, a much higher Ka for phosphate and is inhibited at lower concentrations of 
glutamate compared to the liver isoenzyme. The elegant retrograde and anterograde liver 
perfusion experiments of H3ussinger et al. (67-69) show very clearly that glutaminase 
supplies ammonia to ureagenesis and that glutamine synthetase detoxifies ammonia that 
has escaped the urea cycle. Thus, glutaminase and glutamine synthetase both function at 
the same time in different locations along the liver acinus. 
1.2.2 Perivenous Hepatocytcs in Portacaval Anastomosis 
Girard and Butterworth (62) found that there was a marked loss of glutamine 
synthetase activity in the liver and a small increase in glutamine synthetase in the brain 
and muscle of rats that had received surgical portacaval-shunts. Later it was found that 
there was a signi ficant up-regulation of glutamine synthetase expression in the muscle 
and brain in these animals (45), presumably to deal with excess ammonia that is present 
in the plasma and extracellular fluid post shunt. Nonnally, excess ammonia is converted 
to glutamine by the liver, preventing hyperammonemia. How then would glutamine 
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synthetase activity in the liver decrease? There are two general scenarios which could 
result in reduced glutamine synthetase activity: I) glutamine synthetase expression in 
perivenous cells is reduced or 2) the perivenous cells are lost. From this arises a key 
question: Is perivenous cell function lost in portacaval anastomosis? The fourth paper that 
is presented here addresses this question by measuring the activity and cellular location 
of ornithine aminotransferase, an enzyn1e known to be localized in the same perivenous 
cells as glutamine synthetase (98). 
1.3 Specific Objectives 
Each of the papers discussed include their respective objectives and rationale in 
the introduction sections. However, I will briefly summarize the specific objectives in 
this section. 
Chapter two asks whether the li ver is capable of synthesizing creatine and 
specifically whether arginine produce within the liver can be used for creatine synthesis. 
In addition, we sought to better describe the capacity of the rat liver for creatine 
synthesis. To address these questions we used both in vivo and in vitro experiments. 
Chapter three presents a similar study to chapter two but instead dealing with the role of 
the pancreas in creatine synthesis. This study asks whether pancreatic acinar cells are 
capable of synthesizing creatine and GAA. From the data the capacity of the pancreas for 
creatine synthesis is calculated. In addition, we ask whether the AGAT enzyme in 
pancreas is regulated by dietary creatine supplementation. 
Chapter four sought to detennine whether dietary creatine supplementation can 
improve phosphatidylcholine synthesis in the livers of rats fed high-fat diets. The 
hypothesis was that sparing methyl groups for the PEMT reaction would increase 
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phosphatidylcholinc synthesis, thereby improving hepatic VLDL packaging and 
secretion, and would thus alleviate the accumulation of triglycerides in the liver. The 
specific objectives were to analyze lipid accumulation in the livers of these animals, 
measure the phospholipids and the expression of some genes involved in lipid 
metabolism. 
Chapter five addresses the fate of perivenous hepatocytes in the livers ofrats that 
have undergone surgical portacaval shunts. It has been suggested previously that the 
perivenous cells are lost after portacaval shunting based in the observation that glutamine 
synthetase activity and expression are dramatically reduced in this condition (45, 62). To 
detennine whether the perivenous cells arc lost we specifically sought to measure the 
activity and expression of omithine aminotransferase and an ammonia transporter 
(RhBG) respectively; two enzymes that are colocalized in the perivenous cells along with 
glutamine synthetase. 
1.4 Goals and Outlook 
The overall goal of this thesis is to expand on the field of amino acid metabolism 
in the liver. The works that are presented arc meant to address some current questions. 
The goals arc to detcnninc the role of the liver and pancreas in total body creatine 
synthesis in the rat and to examine the effects of dietary creatine in a model of NAFLD. 
In addition I wished to examine the organization of the liver with respect to perivenous 
amino acid metabolism in portacaval-shunted rats. The creatine projects have 
implications in the understanding of inter-organ amino acid metabolism, net amino acid 
utilization and hepatic methylation reactions. The portacaval shunt project has 
implications in hepatic zonation, hepatic encephalopathy and the balance between 
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glutamate, glutamine and ammonia. Before continuing to the next section I wi ll leave you 
with quotations from two Nobel Laureates who worked in very different fields. 
" It is not enough to say that we cannot know or judge because all the 
infonnation is not in. The process of gathering knowledge does not lead to 
knowing. A child's world spreads only a little beyond his understanding while 
that of a great scientist thrusts outward immeasurably. An answer is 
invariably the parent of a great family of new questions. So we draw worlds 
and fit them like tracings against the world about us, and crumple them when 
we find they do not fit and draw new ones." 
- John Steinbeck - Nobel Prize in Literature 1962 
"The important thing is not to stop questioning. Curiosity has its own reason 
for existing. One cannot help but be in awe when he contemplates the 
mysteries of eternity, of life, of the marvelous structure of reality. It is enough 
if one tries merely to comprehend a little of this mystery every day." 
- Albert Einstein - Nobel Prize in Physics 1921 
I think that both of these quotations illustrate the passion about science shared by most 
and perhaps more importantly the understanding that no matter how great achievements 
may seem, they arc often built on relatively small discoveries. 
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Chapter 2 
Creatine Synthesis: Hepatic Metabolism of Guanidinoacctate and Creatine in the Rat, in 
virro and in vivo 
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2.1 Abstract 
Since creatinine excretion reflects a continuous loss of creatine and creatine 
phosphate, there is a need for creatine replacement, from the diet and/or by de novo 
synthesis. Creatine synthesis requires three amino acids, methionine, glycine and 
arginine, and two enzymes, L-arginine:glycine amidinotransferase {AGAT), which 
produces guanidinoacetate {GAA), and guanidinoacetate mcthyltransfcrase (GAMT), 
which methylates GAA to produce creatine. In the rat, high activities of AGAT are found 
in the kidney, whereas high activities of GAMT occur in the liver. Rat hepatocytes 
readily convert GAA to creatine; this synthesis is stimulated by the addition of 
methionine, which increases cellular S-adenosylmethionine concentrations. These same 
hepatocytes are unable to produce creatine from methionine, arginine and glycine. ISN 
from 15NH4Cl is readily incorporated into urea but not into creatine. Hepatic uptake of 
GAA is evident in vivo by livers of rats fed a creatine-free diet but not when rats were fed 
a creatine-supplemented diet. Rats fed the creatine-supplemented diet had greatly 
decreased renal AGAT activity and greatly decreased plasma [GAA] but no decrease in 
hepatic GAMT or in the capacity of hepatocytes to produce creatine from GAA. These 
studies indicate that hepatocytes are incapable of the entire synthesis of creatine but are 
capable of producing it from GAA. They also illustrate the interplay between the dietary 
provision of creatine and its de novo synthesis and point to the crucial role of renal 
AGAT expression in regulating creatine synthesis in the rat. 
Keywords: inter-organ metabolism, in vivo hepatic fluxes, S-adenosylhomocysteine, 
methylation demand 
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2.2 Introduction 
In vertebrates, creatine and creatine phosphate function as a "buffer" for A TP in tissues, 
maintaining ATP levels when energy demand is transiently greater than the rate of ATP 
synthesis. They also serve in an energy shuttle between the sites of A TP synthesis and 
utilization ( 16). Creatine can be obtained from the diet and/or synthesized de novo in the 
body from the amino acids arginine, glycine and methionine. The entire pathway of 
creatine synthesis consists of just two enzytne·catalyzed reactions (Figure 2.1 ). First the 
amidino group from arginine is transferred to the amino group of glycine, yielding 
ornithine and guanidinoacetic acid (GAA). This is catalyzed by the enzytne 
arginine:glycine amidinotransferase (AGAT). GAA can then be methylated on the 
original glycine nitrogen using S·adenosylmethionine (SAM) as the methyl donor. This 
reaction yields creatine and S·adenosylhomocysteine (SAH) and is catalyzed by the 
enzyme guanidinoacetate N·methyltransferase (GAMT) ( 186). 
The need to synthesize creatine arises from the fact that under physiological conditions 
creatine and creatine phosphate are spontaneously converted to creatinine which is 
subsequently lost to the urine. Daily creatinine loss is estimated to be on the order of 
1.7% of the total body creatine pool or around 2 grams per day in a young 70 kg human 
male (186). Since the total body pool of creatine is constant, the lost creatine must be 
replaced either from the diet or from de novo synthesis. Humans on a typical western diet 
obtain about half of their creatine by synthesis and half from the diet. Vegetarians obtain 
very little dietary creatine so that endogenous synthesis is their major source (153). 
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Figure 2.1 
Creatine biosynthetic pathway. HA; Hepatic Artery, PV; Portal Vein, HV; Hepatic Vein. 
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In the rat, AGAT is highly active in the kidneys while GAMT is highly active in the liver. 
This has given rise to the idea that GAA is synthesized primarily in the kidney and then 
transported to the liver where it is methylated to fonn creatine (186). Evidence to date 
strongly suggests that AGAT is a critical control step in creatine synthesis and it has been 
shown that creatine supplementation down-regulates, while growth hormone up-
regulates, AGA T expression (65, 11 3). The mechanisms by which creatine and growth 
honnone affect the regulation of AGAT expression have not been identified but it is 
known that they affect AGAT synthesis at the pre-translational level (65, 11 3). On the 
other hand, GAMT isolated from pig or rat liver is not inhibited by creatine but is 
competitively inhibited by SAH, as are the other methyltransferases (37, 57). In addition 
to its role in creatine synthesis GAMT should maintain low [GAA], as it has been shown 
that high GAA levels result in neurotoxicity ( 11 8). There is evidence that the regulation 
of creatine biosynthesis in humans is similar to that in the rat. Dietary supplementation 
with 4 glkg diet (similar to the creatine content of red meat) in rats, results in a reduction 
of renal AGA T activity by 86% and plasma GAA levels by 70% compared to control rats 
fed a creatine-free diet (49). Creatine ingestion by humans lowers plasma GAA levels 
which is consistent with down-regulation of AGAT activity (44). 
Recent work from our laboratory has shown that the renal output of GAA in rats fed a 
creatine-free diet is equal to the renal loss of creatinine, indicating that renal GAA 
production is sufficient to replace creatine and creatine phosphate lost to creatinine 
fonnation (49). This implies that in this species extra-renal tissue(s) must convert the 
GAA released by the kidney to creatine. In humans however, the renal production of 
GAA appears to represent only 20% of the daily loss of creatinine (49), suggesting that 
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GAA must be synthes ized in other tissues. It has been proposed by Brosnan and Brosnan 
that the entire creatine synthetic pathway may occur in the li ver (28). They coined the 
tcnn "Arginine Bicycle" to illustrate a situation where arginine could be acted upon by 
either arginase to fonn urea or by AGAT to fonn GAA; in either case ornithine would be 
fonned and metabolized via the urea cycle enzyme ornithine transcarbamoylase. There is 
also evidence for appreciable expression of AGAT mRNA in human liver (189). Despi te 
past fai lures to measure AGAT activity under standard assay condi tions in rat liver, there 
is immunohistochemical evidence for the AGA T protein in the cytosol of rat hepatocytes 
(1 12). The goal of this paper is to examine creatine synthesis by the rat li ver both in vivo 
and in vitro. We also sought to establish whether AGAT is functionally active in this 
ti ssue. Our results show a brisk production of creatine from GAA by hepatocytes in vitro, 
as well as an hepatic uptake of GAA in vivo . We could find no evidence for a functional 
AGAT in the li ver despite using very sensitive methods 
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2.3 Materials and Methods 
Reagents: HPLC-grade methanol was obtained from Fisher Scientific Ontario, Canada. 
15NH4CI was obtained from Cambridge Isotope Laboratories Inc. All other chemicals and 
reagents were obtained from Sigma. 
Animals: Male Sprague-Dawley rats 250-350 grams were used for all experiments. 
Animals were housed on a 12:12 hour light:dark cycle and fed Purina Rodent Chow 5001 
ad libitum. Rats used for the detem1ination of hepatic fluxes of GAA and creatine were 
fed a purified AIN-93G diet either free of creatine or supplemented with 0.4% creatine 
monohydrate, by weight, in place of an equivalent amount of com starch. Rats were 
anesthetized with sodium pentobarbital, i.p., at a dose of60 mg/100 grams body weight. 
All procedures were approved by Memorial University of ewfoundland Institutional 
Animal Care Committee and were in accordance with the Guidel ines of the Canadian 
Council of Animal Care. 
Isolated Hepatocytes: Rat hepatocytes were prepared as described by Seglen (147). 
Viability of hepatocytes was measured by trypan blue exclusion. Average viability was 
95%. All hepatocyte incubations were carried out at 37°C in a shaking water bath using 
25 mL glass Erlenmeyer flasks with rubber stoppers. Substrates were prepared in Krebs-
Henseleit medium (Containing 1.3 mM calcium) and gassed with 95% 0 2/5% C~. 
Incubations were begun by the addition of aliquots of hepatocyte suspension to the 
Krebs-Henseleit medium containing the substrates. Each flask was gassed with 95% 
0 215% C02 for 20 seconds after the hepatocytes were added and then stoppered. 
Incubations were carried out in triplicate. Incubations were stopped with the addition of 
100 J.LL of ice-cold 30% (w/v) pcrchloric acid. Precipitated protein was pellctcd at 10,000 
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x g for I 0 minutes at room temperature. 700 tLL of the supernatants were removed and 
neutralized with 20 t£L of universal indicator, 40 t£L of 50% K2C0 3 and 20% KOH until 
the pH was between 6 and 8. After standing in ice for 15 minutes, precipitated salts were 
removed by centrifugation at 10,000 x g for 5 minutes at room temperature. Supernatants 
were then assayed for creatine as described below. Hepatocytes incubated for SAM and 
SAH measurement were pelleted at 3000 x g for 2 minutes at room temperature and 
flash-frozen in liquid nitrogen after removal of the supernatant. 
Hepatic Blood Sampling: Blood sampling was perfonned while rats were under 
anesthesia. Blood was drawn into chilled heparinized syringes, and centrifuged for 15 
minutes at 4,000 x g at room temperature and plasma was removed and stored at -20°C 
until analysis. Samples were drawn from the hepatic vein, the hepatic portal vein and the 
abdominal aorta. The hepatic vein was accessed via cannulation of the right jugular vein 
with PE 50 tubing. The position of the catheter tip was visually confinned before and 
after blood was withdrawn. Hepatic uptake and output was calculated from the 
concentrations in these three vessels, by assuming that the portal vein accounted for 75% 
of hepatic blood flow and the hepatic artery accounted for 25% (135). 
Creatine, GAA, SAM and SAH measurement: Creatine was assayed enzymatically and 
by HPLC. The enzymatic method was perfonn ed as previously described ( I 07) except 
that the assay was scaled down for use in 96 well microplates. The absorbance was 
measured in a Molecular Devices SpcctraMAX 190 spectrophotometer, using Softmax 
Pro software, version 3.1.1. The creatine concentration was detenn ined by reference to a 
standard curve. Both GAA and creatine were assayed by the HPLC method of 
Buchberger and Ferdig (29). GAA and creatine were derivatized with ninhydrin and the 
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product was separated on a CIS reverse phase YMC column, (3 ~m particle size and 12 
nm pore size, Waters) employing a Waters 600E solvent delivery system and a Waters 
717 autosampler. The derivatized products were detected by means of a Shimadzu RF-
535 fluorescence detector using an excitation wavelength at 390 nm and an emission 
wavelength at 470 nm. SAM and SAH were assayed by HPLC using a previously 
described method (80). SAM and SAH were extracted by adding 3 volumes of 8% TCA 
to cell pellets, which was then centrifuged at 12,000 x g for 10 min at room temperature; 
supernatants were filtered through a 0.45 J.tlll nylon membrane and injected onto the 
column. 
GAMT and AGAT Assays: GAMT was assayed using a modification of the previously 
described method of Ogawa et al. (126). Fresh rat livers were homogenized in 4 volumes 
of a buffer containing 0.25 M sucrose, 10 mM HEPES and I mM EDTA. Liver 
homogenates were centri fuged at 100,000 x g at 4°C for I hr and the supernatants were 
assayed for GAMT activity. The assay contained 35 mM Tris buffer (pH 7.4), 7 mM 2-
mercaptoethanol, 50 ~M S-adenosylmethionine and 0.2 mM GAA. After a ten minute 
pre-incubation of all the constituents of the assay except GAA, the assay was started by 
the addition of GAA. The blanks did not contain GAA. Homogenates were incubated at 
37°C and were stopped with 75 ~L of 15% (w/v) TCA. This was followed by immediate 
neutralization with 72 ~L of I M Tris pH 7.4. Precipitated protein was pelleted at I 0,000 
x g for 5 min at room temperature and creatine was assayed via the HPLC method 
described above. AGAT was assayed as previously described (164). Total protein was 
assayed using the Biuret method. 
GC Mass Spectrometry: Approximately 500 pl of the neutralized PCA extract of 
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hepatocytes were added into vials containing: saturated aqueous sodium bicarbonate (50 
~L); toluene (600 p.L); and hexafluoroacetylacetone (50 p.L). The mixture was incubated 
for 2 hour at 80°C under continuous stirring, then allowed to cool, centrifuged at 3,000 x 
g for 4 min, and approximately 500 p.L of the upper toluene phase was transferred to 
another vial and dried under nitrogen flow. This solid was suspended in 50 p.L oft-
butyldimethylsilyl (t-BDMS) and incubated for 30 min at 60°C to fonn the t-BDMS 
derivatives. The m/z 344, 345, 346 and 347 ions of the guanidinoacetic acid t-BDMS 
derivative, and the m/z 360, 361, 362 and 363 ions of the creatine t-BDMS derivative 
were monitored. Sample preparation for 15N-Iabcled urea and amino acids was carried out 
as described (25). GC-MS measurements of 15N isotopic enrichment were perfonned on 
either a Hewlett Packard 5970 Mass Selective Detector (MSD) or a 5971 MSD, coupled 
with a 5890 HP-GC, GC-MS Agilent System (6890 GC- 5973 MSD) or Hewlett-Packard 
(HP-5970 MSD), using electron impact ionization with an ionizing voltage of -70 eV and 
an electron multiplier set to 2,000V. 
Data and Statistical Analysis: The linearity of creatine and urea production by isolated 
hepatocytes was tested using linear regression. Creatine production by hepatocytes as a 
function of [GAA] was fitted to a curve using non-linear regression. Plasma values for 
GAA and creatine were analyzed using paired !-tests, pairing different plasma samples 
from the same animal. SAM and SAH data were analyzed using a two-way A NOVA with 
a Newman-Keuls post-test. All other data were analyzed using unpaired Students t-tests. 
All statistical analyses employed Prism Graph Pad software version 3.02. 
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2.4 Results 
Creatine Production by Isolated Rat liepatocytes 
Creatine sysnthesis in hepatocytes was linear with time, for up to 90 minutes, and with 
tissue dry mass, up to 13 mg dry wt/mL of incubation medium. All subsequent studies 
were carried out within these linear ranges. The effect of GAA concentration on the rate 
of creatine synthesis was also examined (Figure 2.2). The data fitted well to a rectangular 
hyperbola and half-maximal GAA concentrations (1 3.3 J.tM) and maximal rates of 
creatine synthesis (2. 1 nmol/hr/mg dry wt) were calculated. The addition of 0.5 mM 
methionine in these rats nearly doubled the maximal rate (3.6 nmollhr/mg dry wt) without 
affecting the half-maximal concentration of GAA. The stimulation of creatine synthesis 
by methionine is likely due to increased provision of S-adenosylmethionine. Incubation 
of hepatocytes with methionine resulted in 2.9 and 2.6-fold increases in SAM over 
controls in the presence and absence of GAA, respectively (Table 2-1). In these same 
incubations SAH increased by 3.4-fold and 3.8-fold, respectively. The addition of 
methionine or GAA significantly lowered the ratio of SAM to SAH compared to the 
control; however incubations with both methionine and GAA did not result in a further 
lowering of this ratio. 
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Figure 2.2 
Effect of[GAA] on creatine synthesis. Hcpatocytcs were incubated with varying [GAA], 
with {A ) or without (• ) 0.5 mM methionine. Each flask contained an average of6.5 mg 
dry mass of cells and was incubated at 37°C for 60 minutes. n=4. Data arc expressed as 
mean ± S.D. and fit to a curve using non-linear regression. P< 0.05 taken as significant. 
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Table 2-1 
Effect of added methionine and GAA on hepatocyte SAM and SAH levels and on the 
SAM/SAH ratio . 
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I 
I 
GAA Control Methionine 
SAM 63.4 ± 13.1 167.9 ± 24.4' 
SAH \0.2 ± 2.4 38.5 ± 3.7' 
SAM/SAH 6.3 ± !.It 4.4 ± 0.8' 
SAM + 54.7 ± 6.7 156.5 ± 17.4' 
SAH + 12.6 ± 2.7 42.6 ± 5.4' 
SAM/SAH + 4.5 ± 0.8 3.7 ± 0.6 
Hepatocytes were incubated for 60 min at 37°C and were incubated 0.5 mM methionine 
and 125 ~M GAA. Data are expressed in nmoles/g wet mass of liver cells as the mean ± 
SD. p<0.05. n~4 
• Indicates significant difference from the controL t Indicates significant difference from 
corresponding incubations with GAA. 
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Creatine Synthesis in the Intact Rat 
We next examined the fluxes of GAA and of creatine across the liver in rats fed both 
creatine-free and creatine-supplemented diets (Figure 2.3). Creatine-supplementation had 
a marked effect on circulating GAA concentrations which were decreased by about 60% 
compared to the rats fed the creatine-free diets. There was no difference between the 
GAA concentrations of any of the vessels serving the liver in rats fed the creatine-
supplemented diet. Hence, in these animals there was no significant hepatic uptake or 
output ofGAA (Figure 2.3A). In contrast, there was a significant hepatic uptake ofGAA 
in the rats fed the creatine-free diet (Figure 2.38). The net concentration difference across 
the liver, around 3.7 )JM, was quite appreciable, amounting to more than 70% of the 
GAA avai lable in the portal vein and hepatic artery. 
We also measured creatine levels in the plasma samples (Figure 2.4). Circulating creatine 
levels were about four-fold higher in the creatine-supplemented rats than in those fed 
creatine-free diet. There was no difference between the creatine levels in any of the three 
vessels in the rats fed either the creatine-free or creatine-supplemented diet (Figure 2.4). 
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Figure 2.3 
Differences in plasma GAA concentration across the liver ofrats fed a diet supplemented 
with 0.4% creatine A, and rats fed a diet free of creatine B. Plasma values are represented 
as fo llows: arterial (clear), portal vein (light grey), hepatic vein (dark grey), concentration 
difference across liver (hatched). Different letters indicate a statistically significant 
difference (p<0.05) between the different blood vessels. The asterisk denotes a significant 
difference (p<0.05) between the vascular inflow and outflow values. The hepatic inflow 
was calculated as described in the text. Data arc expressed as mean ± S.D. n=6. 
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Figure 2.4 
Differences in plasma creatine concentration across the liver of rats fed a diet 
supplemented with 0.4% creatine A, and rats fed a diet free of creatine B. Plasma values 
are represented as fo llows: arterial (clear), portal vein (light grey), hepatic vein (dark 
grey), concentration difference across li ver (hatched). There was no significant difference 
(p>O.OS) between the creatine concentrations in the different vessels. The data are 
expressed as mean ± S.D. n=6. 
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Enzyme Activities for the Enzymes of Creatine Synthesis 
The activities of the enzymes involved in creatine synthesis were measured in rats that 
had been fed creatine-supplemented and creatine-free diets (Figure 2.5). Renal AGAT 
activity was depressed by 84% in rats fed a diet supplemented with creatine. Hepatic 
GAMT activity did not differ between the rats fed creatine-free or creatine-supplemented 
diets. There was no difference in the rate of creatine synthesis from GAA between 
hepatocytes isolated from rats fed a creatine-free or creatine-supplemented diet. 
Stable isotope Analysis of Creatine Synthesis in Rat Hepatocytes 
Hepatocytes incubated with 15N-ammonium chloride as well as methionine and glycine, 
but without GAA, produced urea at a linear rate, under all substrate conditions. 
Incubations were perfonned both in the presence and absence of ornithine as it has been 
shown to inhibit the activity of AGAT (1 73). We were unable to detect creatine in these 
incubations using the enzymatic method and we were only able to detect trace amounts of 
creatine, which were present at time zero, using the HPLC method. However, there was 
no increase in creatine after incubation. Isotopic analysis showed significant enrichment 
of both M+ l and M+2 isotopomers of urea; however, only trace enrichment was found in 
creatine (Table 2-2). 
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Figure 2.5 
Enzyme activities of AGA T and GAMT, and creatine production by hepatocytes isolated 
from rats fed di fferent diets. Renal AGAT activity, A; hepatic GAMT activity, B; and 
creatine synthesis in hepatocytes, C, the clear bars represent rats fed the creatine-free 
diets and the shaded bars represent rats fed the creatine-supplemented diets. Hepatocytes 
were incubated with 0.5 mM methionine and 125 J.LM GAA at 37°C for 60 min. All 
values are expressed as mean ± S.D. The asterisk indicates statistical significance p<0.05. 
n=4. 
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Table 2-2 
Isotopic enrichment of urea and creatine in hepatocyte incubations with 15N-ammonium 
chloride. 
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Urea(M+ I) Urea(M+2) Creatine (M+ I) Creatine (M+2) 
-ornithine 43.0 ± 10.6 55.3 ± 6.1 2.9 ± 3.5 4. 1 ± 4.7 
+ ornithine 38.3 ± 7.9 61.3 ± 6.0 1.9 ± 1.8 5.9 ± 5.9 
Incubations included 5 mg dry mass hepatocytes for 30 minutes at 37°C. Hepatocytes 
were incubated with I mM 15N-ammonium chloride, 2 mM pyruvate, 0.5 mM 
methionine, I mM glycine and I mM ornithine where indica1ed. Values are expressed as 
atom percent excess. n=4 
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2.5 Discussion 
We have clearly demonstrated that rat hepatocytes can convert GAA to creatine. This is 
consistent with our previous finding that isolated hepatocytes released 50% more 
homocysteine when incubated with methionine and GAA compared to cells incubated 
with methionine alone (152). The average maximal rate for creatine synthesis of 3.08 
nmol·min·1-mg dry wf1 in hepatocytes found in this study corresponds well with the 
increase in the rate of homocysteine export reported by Stead eta!. (1 52). Our data agree 
with the notion of methylation demand suggested by Stead et al. (152), i.e. that 
methylation is sensitive to increases in substrate concentration. In this regard it should be 
noted that Stead et al. (152) found that feeding GAA to rats increased plasma 
homocysteine, while feeding creatine reduced plasma homocysteine. 
How well can the synthesis of creatine by isolated hepatocytes account for creatine 
synthesis in vivo? The liver of a 250 g rat weighs about 10 g, of which 70% is water. 
Using our maximal rates of creatine synthesis by isolated hepatocytes (3.08 nmol·min· 
1
·mg dry wr1) we can calculate a maximum in vivo rate of hepatic creatine synthesis of 
221 ~-tmoles·24 h' 1· 250 g raf1• However, a more physiological estimate requires that we 
take into account the substrate levels that occur in vivo. The Km of GAMT for SAM has 
been reported to be 49 J.tM (3 7) and hepatic SAM levels are almost 200 nmoles/g (9), 
therefore, assuming that SAM is unifonnly distributed in the different cell compartments, 
it is likely that in vivo SAM levels are not nonnally limiting. However, in vivo levels of 
GAA arc certain to be a limiting factor. It is therefore necessary to take into account the 
[GAA] that is presented to the liver (about 5 J,tM) and the [GAA] required for half· 
maximal rates of creatine synthesis by isolated hepatocytes (about 13.3 J.tM). Using these 
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data we can predict an in vivo rate of hepatic creatine synthesis of about 60 p.mol/24 
h/250 g rat. We can compare this to the rate of hepatic GAA uptake in vivo, by 
multiplying our [GAA] difference across the liver (3.7 JLM) by the hepatic venous plasma 
flow rate (4.32 mUmin/100 g body wt) reported by Welboume eta\. ( 183). Such a 
calculation yields a rate of hepatic GAA uptake of 57 p.moles/24 h/250 g rat. The close 
agreement between these two estimates reflects the physiological relevance of our in virro 
experiments. We may also compare these data to the rate of urinary creatinine excretion 
from rats on creatine-free diets, about 55 p.moles/24 hr/250 g rat (data not shown). It is 
probably somewhat fortuitous that these numbers are in such close agreement. 
Nevertheless, allowing for the assumptions required for these calculations, it is evident 
that the liver is the major producer of creatine in the rat and that our in vitro studies with 
hepatocytes are a good reflection of the situation in vivo. We do not, however, imply that 
the liver is the sole site of creatine synthesis. Both AGAT and GAMT occur in tissues 
other than kidney and liver. In particular, it is known that the brain can synthesize 
creatine ( 186). The CNS may even be considered as autonomous in creatine synthesis as 
there is evidence that the blood brain barrier is poorly permeable to creatine (22). 
Our results also show that rat liver in vivo can clear over half of the GAA presented to it; 
to our knowledge this is the first time this has been shown. Creatine output by livers of 
animals fed creatine-free diets in vivo did not attain statistical significance. However, 
given that plasma creatine in these animals is about 70 p.M, the production of an 
additional 3.7 J.tM by the liver would be too small for us to reliably demonstrate. 
However the clear uptake of GAA by the liver in vivo and the demonstration of creatine 
synthesis from GAA by isolated hepatocytes indicates that the liver produces creatine in 
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vivo and thus would require a means by which creatine exits the liver. Creatine 
transporters have been described in muscle (12 1), brain, kidney and intestine (24). These 
areNa+· and cr -dependent active transporters which concentrate creatine intracellularly. 
Intracellular to extracellular creatine gradients of greater than I 00 to I are known in 
skeletal muscle (24). However such transporters seem inappropriate for the liver. We 
have found creatine levels to be approximately 0.25 J,tmole·g·1 in freeze-clamped rat li ver 
(data not shown). Therefore the concentration gradient in liver is outward. We suggest 
that hepatocytes may express a novel creatine transporter as well as a GAA transporter. 
These issues have not yet been explored. 
With respect to the question of whether the entire pathway of creatine synthesis occurs in 
rat hepatocytes, we must conclude that it does not. Using a highly sensitive HPLC 
method (limits of detection, 25 nM), we were unable to detect creatine production by 
isolated hepatocytes incubated with pyruvate (as a source of energy as well as a source of 
oxaloacetate for aspartate production) and 15N-ammonium chloride, methionine and 
glycine. This was confirmed by the absence of significant isotopic enrichment of creatine 
from 15N-ammonium. In these same incubations, there was synthesis of urea, together 
with substantial labeling of urea. A significant flux of arginine derived from the urea 
cycle into the creatine synthetic pathway would yield similarly labeled creatine. Thus we 
conclude that the entire creatine synthetic pathway does not occur in rat hepatocytes. We 
caution however that this may be a species-specific observation and that in other 
mammals the liver may contain funct ional AGAT activity and thus the entire creatine 
synthetic pathway. There is considerable variability in the tissue distribution of AGAT 
and GAMT activities among different species ( 162). As discussed in the introduction, 
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renal production of GAA in humans is only 20% of creatinine Joss and thus humans are 
likely candidates to have the entire creatine synthetic pathway in the liver. To our 
knowledge, there has been only one study by Sandberg et al. (139) that reported GAA 
uptake by human liver. However, we do not consider this result to be reliable because the 
reported plasma [GAA], of about 20 p.M, is some 4 to 5-fold than reported by modem 
techniques (49, 145, 156). This discrepancy is likely due to the use of the older Sakaguchi 
colorimetric method which is not specific for GAA; in particular, arginine interferes in 
this assay. 
Finally, our results shed light on the regulation of creatine synthesis in the rat. The 
feeding of creatine decreased neither the hepatic GAMT activity nor the capacity for 
creatine synthesis by isolated hepatocytes. This contrasts vividly with the massive down-
regulation of renal AGAT in such animals (49, 11 3). We also confinned the finding of 
Edison et al. (49) that creatine feeding markedly reduces circulating GAA levels, from 
about 5pM to about 2pM. Since the [GAA] for half-maximal rates of creatine synthesis 
in hcpatocytes is about 13 J.LM, hepatic creatine synthesis should be almost directly 
proportional to circulating [GAA]. This, in tum, indicates that creatine synthesis in rats is 
primarily regulated in the kidney rather than the liver. 
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Chapter 3 
Rat Pancreatic Acini Synthesize Guanidinoacetate and Creatine from Amino Acids 
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3.1 Abstract 
Creatine is an important molecule involved in cellular energy metabolism. 
Creatine is spontaneously converted to creatinine at a rate of I. 7% per day; creatinine is 
lost in the urine. Creatine can be consumed in the diet or synthesized from endogenous 
amino acids through the action of the enzymes arginine:glycine amidinotransfcrasc 
(AGAT) and guanidinoacetate N-methyltransferase (GAMT). The immediate precursor 
of creatine is guanidinoacetatic acid (GAA) which is synthesized from arginine and 
glycine. The liver contains the GAMT enzyn1e and the kidney contains AGAT activity. 
Although the pancreas contains both AGAT and GAMT, its role in creatine synthesis has 
not been fully characterized. We examined the enzymes of creatine synthesis in the 
pancreas as well as the synthesis of GAA and creatine by isolated pancreatic acini. We 
also examined whether these pancreatic enzyn1es were regulated by dietary creatine. We 
found that the pancreatic acini have activities of both AGAT and GAMT and have the 
capacity to synthesize guanidinoacetate and a small amount of creatine. Finally we found 
that dietary creatine supplementation led to a decrease in AGAT activity in the pancreas 
though it did not affect its mRNA or protein abundance. This contrasts with the reduction 
of AGAT enzyn1e activity, mRNA and protein abundance in the kidney suggesting that 
the regulatory mechanisms that control the expression of this enzyme in the pancreas are 
different from those in the kidney. 
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3.2 Introduction 
Creatine is a key molecule for the maintenance of cellular A TP in cells such as 
those in muscle and brain which contain high activities of creatine kinase. Creatine and 
creatine phosphate together with the enzyme creatine kinase act as a buffer for A TP in 
cells. In addition, creatine phosphate is a carrier of "high energy" phosphate between 
sites of A TP synthesis and utilization ( 188). Creatine and creatine phosphate are 
spontaneously converted to creatinine at a rate of about I. 7 % per day and this is lost in 
the urine (186). Therefore the maintenance of constant levels of creatine in the body 
means that this quantity of creatine must be replaced. Creatine can be obtained in the diet 
by ingestion of meat and dairy products and through endogenous synthesis from amino 
acids. 
Creatine is synthesized de novo from the metabolism of the amino acids arginine, 
glycine and methionine. Two enzymes are involved in its synthesis; arginine:glycine 
amidinotransferase (AGAT} and guanidinoacetate N-methyltransfcrase (GAMT). AGAT 
cataly-Les the transfer of the amidino group of arginine onto the nitrogen of glycine, to 
give ornithine and guanidinoacetate (GAA). GAMT is then responsible for the transfer of 
a methyl group from S-adenosyhnethionine (SAM) onto the alpha amine of GAA which 
gives creatine. In vertebrates the highest activities of GAMT arc found in the liver, 
pancreas and brain whi le the highest activities of AGAT have been measured in the 
kidney, pancreas and brain (162). 
We have recently shown that the rat kidney can produce GAA in sufficient 
quantities to replace creatinine lost in the urine (49). In addition, we have shown that the 
liver has a maximum capacity to methylate GAA that is far greater than that required to 
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replace the daily loss of creatine (39). However, the actual hepatic methylation of GAA is 
limited by the delivery of GAA. What then is the function of the creatine synthetic 
enzymes in the other tissues, such as brain and pancreas? Creatine synthesis in the brain 
has been thoroughly examined by Braissant and Henry (22) who suggest that the adult rat 
brain may be able to produce enough creatine to satisfy its own requirements. Although 
the activities of the enzymes responsible for creatine synthesis have been reported to be 
quite high in the pancreas, the role of this organ in creatine synthesis is not yet clear. 
In the present study we ask whether the pancreas is capable of synthesizing 
creatine from amino acids. Sorensen et al. ( 150) have found that the catalytic activity and 
immunoreactivity of AGAT is primarily found in the pancreatic acini rather than the islet 
cells. Therefore we use isolated pancreatic acini to examine the effects of various 
substrates on the synthesis of GAA and creatine. Also, since there is a known down-
regulation of AGA T in the kidney by dietary creatine supplementation, we examine 
whether creatine exerts a regulatory action on the enzyn1es of creatine synthesis in the 
pancreas. 
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3.3 Materials and Methods 
Animals: Male Sprague·Dawley rats, between 250 and 350 grams body weight, were 
used for the experiments. All animals were fed ad libitum and kept on a 12: 12 hr 
light:dark cycle in a climate-controlled room. Control animals were fed the AIN-93G 
diet. For the creatine supplementation study the experimental group was fed an AIN-93G 
diet that contained 0.4% creatine, by weight, in place of an equivalent amount of com 
starch. Both diet groups were fed for a period of 14 days. Surguries were perfon11ed in 
the morning when the rats were still in the absorptive state. All procedures were approved 
by the Memorial University of Newfoundland Institutional Animal Care Committee and 
were in accordance with the Guidelines of the Canadian Council of Animal Care. 
Tissue Collection: Rats were anesthetized with sodium pentobarbital, i.p., at a dose of 
65 mg/kg body weight. The pancreas was removed for the isolation of acini, and 
measurement of GAMT activity as described in detail below. The kidneys and a portion 
of the pancreas were freeze.cJamped in aluminum tongs pre·cooled in liquid nitrogen and 
stored at ·80°C for analysis of metabolites, mRNA and AGAT activity. 
Isolation of Pancreatic Acini: Pancreatic acini were isolated according to a modification 
of a previously published method (18). Immediately after removal from the rat, the 
pancreas was placed in a Petri dish where any visible adipose tissue was dissected and 
separated from the pancreatic tissue. The pancreas was then injected with 5 mL of 
Solution A; Krebs·Henseleit solution containing 1.3 mM calcium chloride, I 0 mM 
glucose, 2.1 mM lactate, 0.15 mM pyruvate, 0.2% w/v fatty acid free bovine serum 
albumin (BSA) and 135 U/mL collagenase (type 4). It was then placed in a 50 mL 
Erlenmeyer flask, together with 25 mL of Solution A. The atmosphere in the flask was 
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replaced with 95% 0 215% C02 by gassing for 30 seconds and the flask was stoppered and 
placed in a shaking water bath at 37° C for 15 minutes. A continuous stream of 95% 
0 2/5% C0 2 gas was fed through the stopper throughout the isolation procedure. After 15 
minutes, the collagenase (Type 4) solution was removed, fresh Solution A (without 
collagenase) was added and the flask shaken for another 15 mintues. This wash was 
repeated once more. Solution A was then removed and 10 mL of solution B was added to 
the flask. Solution B had the same composition as Solution A but with 4% BSA and 
without collagenase. The pancreas was gently teased apart by repetitive pipetting through 
plastic pipettes with decreasing bore sizes. The suspension was passed through a 250 J.un 
fi lter and centr ifuged at 200 x g for 2 minutes. The supernatant was removed and the 
acini were resuspended in fresh solution B. This wash was repeated three times. Finally 
the acini were re-suspended in Krebs-Henseleit medium containing 0.2% BSA. Viability 
was assessed by means of trypan blue exclusion. Because acini are isolated in their multi-
cell ultrastructure quantitative detennination of viability was impossible. Therefore a 
qualitative estimation of viability was perfom1ed for each isolation procedure. 
Incubations were initiated by the addition of aliquots of the pancreatic acini 
suspension into pre-warmed (3 7°C) 25 mL Elenmyer flasks containing Krebs-Henseleit 
medium and substrates. The substrates were prepared in Krebs-Hcnseleit medium. The 
atmosphere inside each Erlemneyer flask was replaced with 95% 0 2/5% C02 by gassing 
for 20 seconds and sealing with a rubber stopper. Incubations were carried out in 
triplicate. Incubations were stopped by the addition of 100 1-'L of icc-cold 30% (w/v) 
perchloric acid. Precipitated protein was pelleted at I 0,000 x g for I 0 minutes at room 
83 
temperature. 700 J.tL of the supernatants were removed and neutralized with 20 J.tL of 
universal indicator, 40 J.tL of 50% K2C03 and 20% KOH until the pH was between 6 and 
8. After standing in ice for 15 minutes, precipitated salts were removed by centrifugation 
at 1 0,000 x g for 5 minutes at room temperature. Supernatants were then assayed for 
creatine as described below. Aliquots of cells that were not subjected to de-proteinization 
were assayed for GAMT and AGAT activity as described below. 
Enzyme Acth•ities: GAMT was assayed on fresh tissue according to a previously 
described method (39). AGAT was assayed on fresh or frozen tissue as previously 
described (164). Total protein for all tissue homogenates was assayed using the Biuret 
method. 
Real-time PCR: Frozen pancreatic and kidney tissue (-80°C) were ground to a fine 
powder in a ceramic mortar and pestle pre-cooled with liquid N2• Approximately 100 mg 
of powdered tissue was placed in a sterilized microcentrifuge tube containing 500 J.tL of 
ice-cold Trizol reagent and immediately homogenized with a hand-held electronic 
homogenizer. Total RNA was extracted using the standard Trizol extraction procedure 
provided by Invitrogen (Burlington, Ontario). RNA quality was assessed by separation on 
an agarose gel and also by measuring absorbance at 260 nm and 280 nm using a nano-
drop spectrophotometer system (Thenno Fisher Limited, Ottawa, Ontario). Primers were 
designed using Primer3Plus onl ine software and obtained from Integrated DNA 
Technologies (Coralville, Iowa). PCR was conducted using a Roche Lightcycler (Laval, 
Quebec) using Lightcycler3 software. The AGAT forward primer was 
"CTGTGCAGCTGAAGACAAGG" and the reverse primer was 
"CTGTGAA TGGTGGGACACAG". GAMT 
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forward primer was 
"ACTCA TGCTTTCCGTTTGCT" and reverse primer was 
"AGGCACCTGAGTCTCCTCAA". Target RNAs were nonnalizcd to ISS ribosomal 
RNA with forward primer "GTGATCCCCGAGAAGTTTCA" and reverse primer 
"CTGCTTTCCTCAACACCACA" 
Creatine, GAA, SAM and SAH memmremelll: GAA and creatine were assayed by the 
HPLC method of Buchberger and Ferdig (29). HPLC was conducted on a Waters 600E 
solvent delivery system and a Waters 7 17 autosampler. SAM and SAI-l were assayed as 
described previously (80). 
Westeru Blots: AGAT protein was detected using an affinity-purified anti-AGAT rabbit 
polyclonal antibody raised against the sequence RPDPIDWSLKYKTPDFE, amino acids 
142-159 of rat AGAT (accession number P50442- l), (Open Biosystems Huntsville, 
Alabama). The secondary antibody was a horseradish peroxidase-conjugated anti-rabbit 
lgG (Bio-Rad Mississauga, Ontario), visualized using the hnmunstar chemiluminescence 
system (Bio-Rad Mississauga, Ontario). Band detection was performed using an 
enhanced luminol system (lmmunn-Star, Bio-Rad inc.) and analysed with an Alpha 
Jnnotech Chemi lmager 4400 (Alpha Innotech, San Leandro, California, USA). 
Reage11ts: All reagents were purchased from Sif:,'llla A ldrich with the exception of 
collagenase, from Worthington (Lakewood, New Jersey), and perchloric acid, from 
Fisher Scientific (Ottawa, Ontario). All reagents used for PCR were purchased from 
Invitrogen (Burlington, Ontario). 
Statistical Analysis: Statistical analyses were pcrfonned on Prism Graph Pad software 
version 3.02. Data were compared using unpaired Students t-tests with the exception of 
the data from the isolated pancreatic acini incubatio ns which were analyzed by one-way 
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ANOVA. P-values less than 0.05 were taken as significant. 
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3.4 Results 
Average pancreas weights were 1.38 ± 0.21 g and 1.47 ± 0. 12 g for the control 
and creatine-supplemented groups, respectively; these were not significantly different 
from each other. 
Rates ofGAA production by pancreatic acini isolated from rats fed a creatine-free 
diet are reported in Table 3-1. Pancreatic acini produced significant quantities ofGAA in 
the presence of methionine, glycine and arginine. In the presence of high concentrations 
of arginine and glycine (2 mM each), GAA production in pancreatic acini was 
approximately 8 fold higher than in the presence of near physiological concentrations of 
these amino acids (0.2 mM each). Pancreatic acini were capable of synthesizing creatine 
under all substrate conditions, although, the rates were much lower than the rates ofGAA 
synthesis. This was consistent with the activities of AGAT and GAMT measured in the 
isolated acini ; the activity ofGAMT was only 2.3% of the AGAT activity. The capacity 
for GAA production in pancreatic acini therefore greatly outstrips the capacity fOr GAA 
methylation (creatine production). 
We examined the pancreatic content of key metabolites, as well as activities, 
mRNA and protein abundance of key enzymes required for creatine synthesis in pancreas 
from rats fed creatine-free or creatine-supplemented diets. The concentrations of selected 
metabolites arc shown in Table 3-2. Pancreatic content of GAA, creatine and creatine 
phosphate was 5-fold, 3-fold and 2-fold higher, respectively, in the creatine-
supplemented animals than in the controls. The elevated concentrations of creatine 
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Table 3-1 
Activities of AGAT and GAMT in, and rates of GAA and creatine accumulation by, 
isolated pancreatic acini. 
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Incubation 
Conditions 
GAA and 
Creatine Production 
GAA 
Creatine 
AGAT Activity 
GAMT Activity 
Zero Time 
0.39 ± 0.14 
0.29 ± 0.12 
5 ~M GAA I 100 ~M GAA 
0.5 mM Methionine 0.5 mM Methionine 
0.95 ± 0.61* 1.14 ± 0.82* 
0.2 mM Arginine 
0.2 mM Glycine 
0.5 mM Methionine 
3.07 ± 0.49* 
1.64 ± 1.45* 
3.41 ± 1.36 nmole/min/ mg protein 
0.08 ± 0.06 nmolelmin/mg protein 
2 mM Arginine 
2 mM Glycine 
0.5 mM Methionine 
21.65 ± 9.01 t 
1.85 ± 1.46* 
GAA and creatine were measured at zero time and after 40 minute incubations in pancreatic acini isolated from rats fed creatine-free 
diets. GAA and creatine accumulation are given in nmoles per mg protein per 40 minutes and expressed as means ± standard 
deviations. An asterisk indicates a significant difference from the zero time incubations. t indicates a significant difference from all 
other incubation conditions. AGA T and GAMT were assayed in isolated acini as described in the methods section (n=6) 
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Table 3-2 
Metabolite concentrations in the pancreas of rats fed creatine.free and creatine-
supplemented diets. 
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~ Creatine-free Diet 0.4% Creatine Diet e 
GAA (JLmoles/g wet tissue) 0.05± 0.04 0.22 ± 0.06' 
Creatine (J.Lmoles/g wet tissue) 0.16 ± 0.05 0.44 ± 0.12' 
Creatine Phosphate 
0.20 ± 0.08 0.37 ± 0.10' 
(/lmoles/g wet tissue) 
ATP (~mo1e/g wet tissue) 0.98 ± 0.33 1.07 ± 0.32 
SAM (nmoles/g wet tissue) 26.57 ± 2.84 17.40 ± 2.77' 
SAH (nmoles/g wet tissue) 1.06 ± 0.39 0.84 ± 0.04 
SAM/SAH 27.2 ± 7.5 20.7 ± 3.7 
Data are presented as means ± standard deviations. An asterisk indicates a significant 
difference between diet groups, (n=5). 
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phosphate in the creatine-supplemented animals are probably a consequence of the 
increased pancreatic creatine levels. The concentration of SAM in the pancreas of 
creatine-supplemented rats was only 65% of the level observed in the control animals. 
The level of SAI-l as well as the SAM-to-SAI-l ratio in the pancreas were not statistically 
different between diet treatments. 
The enzyme activity and relative mRNA expression for AGAT and GAMT in the 
pancreas are given in Figure 3.1 along with the protein abundance of AGAT. Creatine 
supplementation reduced pancreatic AGAT activity by 34% while the protein and mRNA 
were unchanged. Pancreatic GAMT activity and mRNA were not affected by dietary 
creatine. We were unable to measure GAMT protein by western blot due to the lack of a 
suitable antibody. For comparison, renal AGAT activity, protein and mRNA abundance 
are presented in Figure 3.2. There was a much greater effect of dietary creatine on renal 
AGAT activity which was reduced by 83% in rats fed the creatine-supplemented diet. 
Relative expression of AGAT mRNA and protein in the kidneys of creatine-
supplemented animals was also reduced by 47% and 60%. The failure of pancreatic 
AGAT mRNA to be decreased by dietary creatine supplementation suggests that AGAT 
in pancreas is not regulated at the pre-translational level as is the case with renal AGA T. 
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Figure 3.1 
The effect of dietary creatine on pancreatic AGAT and GAMT. AGAT enzyme activity 
(A), integrated density values from AGAT Western blot (B), relative expression of 
AGAT mRNA in pancreas (C), GAMT enzyme activity (0), and relative expression of 
GAMT mRNA in pancreas (E). Creatine-free diets (grey bars) and creatine-supplemented 
diets (hatched bars). Data for mRNA target genes were nom1alized to I&S ribosomal 
RNA. Values are given as means ± standard deviations. An asterisk signifies statistical 
significance (n=5). 
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Figure 3.2 
The effect of dietary creatine on renal AGA T. Enzyme activity (A), integrated density 
values from AGAT Western blot (B) and relative expression of AGAT mRNA in kidney 
(C). Creatine-free diets (grey bars) and creatine-supplemented diets (hatched bars). Data 
for mRNA target genes were nonnalized to 18S ribosomal RNA. Values are given as 
means ± standard deviations. An asterisk signifies statistical significance (n=S). 
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3.5 Discussion 
Signi ficant AGAT activity and GAA production were observed in pancreatic 
acini. This agrees with the immunohistochemical localization of AGAT protein 
exclusively in the pancreatic acini (150) and the detennination of AGAT enzyme activity 
(163) in the pancreas. AGAT has high K111 values for arginine (-1-3 mM) and glycine 
(-2-3 mM) ( 186). This is consistent with the increase in GAA production when the 
concentrations of these amino acids are increased from 0.2 mM to 2 mM. The sensitivity 
to arginine and glycine levels suggests that the transport of these substrates into 
pancreatic acinar cells is not limiting to the synthesis of GAA in the pancreas and hence 
that plasma substrate concentration influences GAA synthesis. However, creatine 
production in pancreatic acini was not different among any of the various substrate 
concentrations. The low activity ofGAMT relative to the AGAT activity may account for 
this observation. Thus, from the rates of GAA and creatine production and the enzyme 
activities measured in pancreatic acini , we must conclude that the capacity for GAA 
synthesis in the pancreas is much higher than the capacity for creatine synthesis. 
In order to gain a better insight into the potential impact that the pancreas might 
have on total body creatine synthesis in the rat, we have made some calculations of 
pancreatic creatine and GAA production. We calculate a rate of creatine synthesis in the 
presence of 0.2 mM arginine, 0.2 mM glycine and 0.5 mM methionine of 4.4 1£moles of 
creatine/day per 250 g rat This compares with the measured loss of creatinine of 55 
1£moles/day/250 gram rat which is equivalent to the daily renal GAA production (49). 
Thus the pancreas could produce as much as 8 %of the creatine that is lost per day. A 
similar calculation of GAA production yields a rate of pancreatic GAA production of 8.3 
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~nnoles of GANday/250 gram rat (15 % renal GAA production). Given that pancreatic 
venous blood drains into the hepatic portal vein and flows through the liver, it is possible 
that the pancreas releases GAA into the plasma to be used for creatine synthesis in the 
liver. 
Dietary creatine significantly elevated creatine and creatine phosphate levels in 
the pancreas. The increase in creatine phosphate probably reflects the action of the 
reversible creatine kinase enzyme. Although the function of creatine in the pancreas is 
not fully understood, there is some suggestion that the creatine kinase system may have 
an effect on A TP levels in the pancreatic islets and thus the secretion of honnones from 
the endocrine pancreas ( 175). A substantial creatine kinase activity has been found in 
islets isolated from mouse pancreas (128) and phosphocreatine has been shown to 
increase response of the K-ATP channels in rat pancreatic islets (96). K-A TP channels 
are integral to the mechanism of release of insulin from the ,8-cells of the pancreas. A 
recent study by RociC et al. (136) supports the role of the creatine kinase system in ,8-
cells, showing that the provision of creatine in the presence of various concentrations of 
glucose significantly increased ATP levels. In addition, RociC et al. showed that insulin 
secretion was increased by the provision of creatine, independent of the presence of 
added glucose (136) which suggests that changes in pancreatic creatine levels alone may 
impact insul in secretion in the ,8-cell. Marco et al. ( 11 0) have shown that creatine, GAA 
and arginine (at quite high concentrations) can significantly increase the secretion of 
glucagon and insulin in isolated pancreatic mouse islets. The mechanism through which 
guanidino compounds affect honnone release from pancreatic islets remains to be 
elucidated. However, there is good evidence from studies using inside-out patch clamps 
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of mouse pancreatic P·cells that the addition of PCr prevented the opening of KA TP 
channels similar to the effect of added ATP suggesting that PCr is involved in the 
regulation of insulin secretion through modulation of A TP and AOP levels ( 146). 
An interesting aspect of creatine metabolism in the pancreas is that it appears 
GAA is synthesized exclusively in the acini (exocrine pancreas) (ISO), while the known 
pancreatic functions of creatine arc located in the islets (endocrine pancreas) (I I 0, 128). 
It is tempting to speculate that the acinar synthesis of GAA and creatine may function to 
provide islets with creatine, rather than supplying the rest of the body. It should be noted 
that creatine is synthesized by some cell types in the brain and concentrated in others 
(21). This might similarly be the case among different cell populations in the pancreas. 
We observed a high ratio of SAM·to·SAH in the pancreas indicating that there is 
a high methylation potential in this tissue. The pancreatic SAM·to·SAH ratio is 6·fold 
higher than that reported by us for the liver (79). There is also evidence that the pancreas 
has a very active methionine cycle. Recently Wilson et al. (184) have shown, in a study 
using metabolic tracers, that the pancreas has the highest production of homocysteine 
from methionine per gram among a comprehensive list of tissues. Creatine 
supplementation appeared to have an effect on pancreatic methylation potential as SAM 
levels were signi ficantly lower in the pancreas of creatine·supplemented rats. Since the 
activities of the methyltransferases are increased in the presence of higher SAM (37) 
these data could suggest that dietary creatine supplementation may have an impact on 
methylation in the pancreas. 
The effect of dietary creatine on AGAT expression and activity appears to be 
different in the pancreas than in the kidney. We found that dietary creatine reduces the 
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activity of AGAT in the pancreas by about 34%. In addition, we found that AGAT 
mRNA and protein expression in the pancreas were unchanged by dietary creatine 
supplementation. This is quite different from what we observed in the kidney. Renal 
AGAT activity, protein and mRNA expression were all significantly reduced in the 
presence of dietary creatine supplementation. This confinns the finding of McGuire et al 
( 11 3) who have shown that both renal AGAT activity and mRNA expression are 
significantly reduced by 74% and 63%, respectively, in the presence of dietary creatine 
supplementation. Our data indicate that the pre-translational mechanism of regulation that 
responds to dietary creatine in the kidney may not occur in the pancreas. 
In summary, we show that pancreatic acini contain activities of both AGAT and 
GAMT enzymes and are capable of producing significant GAA as well as a small amount 
of creatine de novo. The capacity for GAA synthesis is greater than the capacity for 
creatine synthesis. In addition we show different effects of dietary creatine-
supplementation on AGAT activity and expression in the pancreas and kidney which 
implies that the mechanisms of AGA T regulation present in the kidney may not be 
present in the pancreas. 
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Chapter 4 
Creatine supplementation prevents the accumulation of fat in the livers of rats fed a high~ 
fat diet. 
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4.1 Abstract 
The aim of the present study was to examine the effects of creatine 
supplementation on liver fat accumulation induced by a high~ fat diet in rats. Rats were 
fed one of three different diets: control liquid diet, high~ fat liquid diet, or high~ fat liquid 
diet supplemented with creatine. The control and high~fat liquid diets contained, 
respectivel y, 35 and 7 1% of energy derived from fat. Creatine supplementation involved 
the addition of I% (wt/vol) of creatine monohydrate to the liquid diet. The high~ fat diet 
increased total liver fat concentration, liver triglycerides, liver TBARS and decreased the 
hepatic S~adenosylmethionine {SAM) concentration. Creatine supplementation 
nom1alized all of these perturbations. Creatine supplementation significantly decreased 
the renal activity of L~arginine:glycine amidinotransferase and plasma guanidinoacetate 
and prevented the decrease in hepatic SAM concentration seen in rats fed the high~ fat 
diet. However there was no change in either the 
phosphatidylcholine/phosphatidylcthanolamine ratio or phosphatidylethanolamine N~ 
methyltransferase (PEMT) activity. The high~fat diet decreased mRNA for PPARa, as 
well as two of its targets, CPT I a and LCAD. Creatine supplementation nonnalized these 
mRNA levels. In conclusion, creatine supplementation prevented the fatty liver induced 
by feeding rats a high~ fat diet probably by nonnalization of the expression of key genes 
ofbeta~oxidation. 
Key-words: high~fat diet, fatty liver, creatine supplementation, PPARa, fatty acid 
oxidation. 
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4.2 Introduction 
Nonalcoholic fatty liver disease (NAFLO) is one of the most common chronic 
liver diseases throughout the world (2). NAFLO is a clinical pathological state that 
develops in the absence of alcohol abuse and is characterized by the accumulation of 
triglyceride in hepatocytes. It can progress to nonalcoholic steatohepatitis (NASH) and in 
some cases, to fibrosis and cirrhosis ( 48). However, the mechanisms involved in 
nonalcoholic fatty liver disease are uncertain (48, 99). The two-hit model proposes that 
the first hit involves a simple accumulation of fat in the liver, increasing the susceptibility 
of liver to more severe damage by the second hit that involves mitochondrial dysfunction, 
lipid peroxidation and inflammation (41 ). 
Fat accumulation and NASH progression have been associated with impaim1ent 
of methionine metabolism in liver (91), resulting in decreased avai labi lity of S-
adenosylmethionine (SAM) as well as an increase in homocysteine levels and oxidative 
stress (91 , 92). In support of this mechanism, it is known that supplementation with 
betaine, an important methyl donor for the remethylation of homocysteine to methionine, 
may protect the liver from fat accumulation and lipid peroxidation. This has been 
observed in both rodent models of alcoholic (5 1) and non-alcoholic (99) fatty liver. Kwon 
ct at. (99) suggested that the elevation of SAM may play a critical role in the protective 
effect of betaine. 
Creatine occurs naturally in food, especially in meat and fish. Creatine, in the 
fonn of creatine monohydrate, is taken by many athletes for its ergogenic properties. In 
humans, approximately 1-2 g of creatine is required to replace that lost by irreversible 
conversion to creatinine. In human omnivores, half of this is provided in the diet while 
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the remainder is endogenously synthesized (24). The first step in creatine synthesis 
involves the reversible transfer of the amidino group of arginine to glycine to fonn 
guanidinoacetic acid (GAA) and ornithine in a reaction catalyzed by the enzyme 
arginine:glycine amidinotransferase (AGAT); this enzyme is very active in kidneys. 
Next, the irreversible transfer of a methyl group from SAM to GAA is catalyzed by the 
enzyme S-adenosylmethionine;guanidinoacetate N-methyltransferase (GAMT) which is 
most active in the liver. The products of this reaction are creatine and S-
adenosylhomocysteine (SAH). Creatine synthesis is responsible for a considerable 
consumption of SAM in the liver (153), as much as 40% of the total body SAM 
requirement. Previous studies have shown that creatine supplementation down regulates 
renal AGAT activity (49) and therefore the endogenous fonnation of creatine. It also 
reduces homocysteine production (43, 152). Since both phosphatidylethanolamine N-
methyltransferase (PEMT) and GAMT use the same hepatic SAM pool, creatine 
supplementation may increase SAM avai labi lity to phosphatidylcholine fonnation via 
PEMT, thus increasing VLDL secretion and diminishing fat accumulation in liver. 
The aim of the present study was to examine the effects of creatine 
supplementation of rats fed a high-fat diet on liver fat accumulation, methionine 
metabolism and lipid peroxidation. Creatine supplementalion does indeed prevent 
development of fatty liver in response to a high fat diet but by a mechanism other than 
increased SAM availability. 
107 
4.3 Material and Methods 
Animals and lreatmenl 
Male Sprague-Dawley rats (initial weight - 120 g) were obtained from the 
Memorial University of Newfoundland Animal Care Unit. All procedures were approved 
by the Animal Care Conunittee of the same institution and were in accordance with the 
Guidelines of the Canadian Council on Animal Care. The rats were kept in individual 
cages on a 12/ 12 hour light/dark cycle at a mean temperature of2rC and were randomly 
assigned to 3 groups of6 rats each: control (C); high-fat (HF); and high-fat with creatine 
(HFC). Group C was fed with a standard liquid diet with 35% of energy from fat, 18% 
from protein and 47% from carbohydrates (Dyets catalogue # 710027). 
The high-fat groups received a high-fat liquid diet with 71% of energy derived from fat, 
18% from protein and II % from carbohydrates (Dyets catalogue # 712031 ). The diets 
were purchased from Dyets Inc (Bethlehem, PA, USA). The overall compositions of both 
the control and the HF diet, were identical to those described by Lieber et at. (106) 
Creatine supplementation was perfonned by adding I% (wtlvol) creatine monohydrate to 
the high-fat liquid diet. The rats had free access to food throughout the 3 weeks. Food 
intake was measured daily to assess total energy, total fat and creatine consumption. 
Body weight was measured twice a week to detennine the weight gain. 
Tissue preparation 
After the experimental period, the animals were anesthetized with an intra-
peritoneal injection of sodium pentobarbital (65 mglkg i.p.). The fed animals were 
sacri ficed between 8 and 10 am. Blood was collected into heparinized tubes, centrifuged 
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and the plasma stored at -80°C. A portion of the liver was freeze-cl amped with aluminum 
tongs pre-cooled in liquid nitrogen, weighed and stored at -80°C. A portion of fresh liver 
tissue was weighed and cut in small cubes of approximately 5 x 5 x 5 mm and embedded 
using the Optimal Cutting Temperature (OCT) Compound (Leica. Gennany) for Oil-Red-
O histopathologic evaluation. One kidney was removed and immediately homogenized in 
ice-cold 50 mmol/L potassium phosphate buffer (pH 7.4) with a Polytron (Brinkmann 
Instruments, Toronto, ON, Canada) for 25 s at 50% output. This homogenate was used 
for the analysis of AGAT activity. 
Hepatic hisrology and lipid analysis 
For histopathologic evaluation, 7 ttm sections of OCT-blocked liver tissue were 
immersed in propylene glycol for seven minutes and stained with Oil-Red-O for 10 
minutes. The sections were washed 3 times with distilled water, counterstained in 
haematoxylin for 20 min and washed again in distilled water before microscopic analysis. 
Adobe Photoshop® CS3 software {Adobe, San Jose, California, USA) was used to 
estimate the percentage of red pixels in each image. 
Liver total fat was detennined by homogenizing I g of liver in 1.5 mL of distilled 
water; 5 mL of chlorofonn-methanol (2: 1) was added and the tubes were thoroughly 
mixed. After centri fugation, the chlorofonn phase was transferred to a pre-weighed tube, 
the extraction repeated twice and the chlorofonn phases combined, evaporated to dryness 
and re-weighed. The fat was re-suspended in I mL !-propanol for the measurement of 
total liver triglycerides and cholesterol, using commercially available kits from 
Diagnostic Chemicals (Charlottetown, PEl, Canada, catalogue # 236-17 and #234-60, 
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respectively, for triacylglyccrol and cholesterol). Hepatic phosphatidylcholine and 
phosphatidylethanolamine were measured by a phosphorus assay after separation by thin-
layer chromatography, as described by Jacobs eta!. (78). 
Creatine, GAA, and sulfiw-containing metabolites. 
Both GAA and creatine were assayed by the HPLC method of Buchberger and 
Ferdig (29). For SAM and S-adenosylhomocysteine (SAH) detenninations. freeze 
clamped liver samples were homogenized in ice-cold 8% (wt/vol) trichloroacetic acid and 
the homogenates centrifuged at 13,000 g for 5 min at 4°C. The supernatants were 
analyzed by HPLC using a Vydac C1s column (model 2187P54) equilibrated with 96% of 
buffer A (50 mmol/L NaHzP04 containing 10 mmoi/L heptanesulfonic acid at pH 3.2) 
and 4% acetonitrile. SAM and SAH were separated by means of a gradient of96-80% of 
buffer A and 4-20% of acetonitrile for 15 min. SAM and SAH peaks were detected at 258 
nm and quantified using Millenniumn (version 2) software (Waters, Milford, MA). Total 
plasma homocysteine and cysteine concentrations were detennined by reverse phase 
HPLC and fluorescence detection of ammonium 7-tluoro-2-oxa-1,3-diazole-4-
sulphonate (SBDF) thiol adducts by the method of Vester and Rasmussen (168). 
AGAT activity assay and lmmwwblot 
Protein was assayed using the Biuret method. Kidney AGAT activity was 
detennined as described by Van Pilsum eta!. (164). For the Western blotting of kidney 
AGAT, proteins were separated by SDS-PAGE (12% polyacrylamide gel) and transferred 
by electroblotting to nitrocellulose membranes. AGAT-protein was detected using an 
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affinity-purified anti-AGAT rabbit polyclonal antibody raised against the sequence 
RPDPIDWSLKYKTPDFE, amino acids 142-159 of rat AGAT (accession number 
P50442-1) (Open Biosystems, Inc.). The blots were incubated at 4°C overnight with the 
primary antibodies diluted in 5% non-fat dried-milk, followed by 45 min incubation with 
horseradish peroxidase-conjugated anti-rabbit JgG (Bio-Rad), and visualized by 
chemiluminescence. Band detection was perfonned using an enhanced lumina l system 
(Immunn-Star, 144 Bio-Rad) and analysed with an Alpha lnnotech Chcmilmager 4400 
(Alpha Jnnotech, San Leandro, Cali fornia, USA). 
Gene Expression 
Real-time reactions were carried out to analyze the gene expression of PEMT, 
BHMTI, GNMT, MGAT, PPARa, CD36, CPTi a, LCAD, VLCAD and UCP2. Total 
RNA was isolated from frozen liver using Trizol® (Invitrogen). RNA quality was 
assessed with an Agilent 2100 bioanalyzer, using an RNA 6000 Nano kit. Samples were 
treated with DNAse I (Invitrogen) to digest genomic DNA; RNA was then reverse 
transcribed using Superscript II (Invitrogen). Primer sets and a corresponding probe for 
each gene of interest were designed using the Universal Probe Library (Roche) based on 
the NCB\ reference nucleotide sequences for rattus norvegicus. Each primer pair and 
probe combination was tested by qPCR (StepOnePlus, Applied Biosystems). Primer 
mixes for each gene were combined in a single assay which was used to pre-amplify the 
eDNA of the genes of interest in each sample. Pre-amplification was tested using a probe 
for cyclophilin by qPCR. Forty-eight gene assays and eDNA samples were loaded into 
separate wells on a 48-by-48 gene expression chip (Fiuidigm). qPCR was run on the 
Ill 
BiomarkTM system (Fluidigm) for 40 cycles. Relative RNA expression for each gene in a 
sample was standardized to the endogenous housekeeping gene cyclophilin (Ppia), and 
calculated using the comparative threshold (LlLlCT) method. All assays were perfonned in 
triplicate. 
Insulin, glucose and hepatic TBARS 
Plasma glucose was measured using hexokinase and glucose-6-phosphate 
dehydrogenase, as described by Bergmeyer et a!. ( 15). Plasma insulin was measured 
using a commercially available kit from Crystal Chern Inc (catalogue # fNS KR020) 
employing a rat insulin standard. Liver thiobarbituric acid reactive species (TSARS) was 
detennined using commercially available kits from ZeptoMctrix Corporation (catalogue 
#081192). 
Statistical analysis 
Data were reported as mean ± standard deviation (SO). Groups were compared by 
analysis of variance (A NOVA) and orthogonal contrasts were used to identify specific 
differences between pairs of treatments using the SAS statistical package (version 8.2). In 
all analyses, the level of significance was set at P < 0.05. 
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4.4 Results 
There were no differences in body weight gain or food intake for the 3 groups 
during the 3 week experimental period. As expected, fat intake was higher (P < 0.05) in 
HF and HFC than in the control group. The liver weight was elevated in the I-I F group 
and this was prevented by creatine supplementation (Table 4~ I). 
Three weeks of ingesting the high~ fat diet resulted in a significant increase in 
hepatic total fat (55%), triglycerides (87%) and total cholesterol (25%) compared to rats 
fed the control diet. Supplementation of the high~ fat diet with creatine prevented the 
hepatic accumulation of these lipids. Increased hepatic TSARS was evident after three 
weeks of feeding the high-fat diet. This increase was prevented by creatine 
supplementation (Table 4~2). The effects of creatine supplementation on liver fat were 
clearly evident in the Oii~Red~O~stained histological sections {Figure 4.1). The difference 
in fat accumulation between I-I F and HFC sections was confim1ed by image analysis. 
Ingestion of the I-IF diet increased plasma glucose which was partiall y reversed by 
creatine supplementation. Plasma insulin concentration did not differ between the groups. 
The plasma creatine concentration increased significantly in the HFC group. The 
HF diet decreased the liver SAM concentration by 18% when compared with C group. 
Creatine supplementation prevented the decrease in li ver SAM concentration in I-I FC rats, 
maintaining it at the same level as the control group. No changes were found in plasma 
Hey concentration between the groups. Creatine supplementation increased plasma 
cysteine; the reason for this is not known {Table 4~3). 
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Table 4-1 
Weight gain, liver weight, and intake of energy, fat, and creatine in rats fed Control (C), 
high-fat (HF), or HF liquid diet with creatine (HFC) for 3 wk. 
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c Hf HFC 
Weight gain (g) 184 ± 21 193 ± 16 174 ± 13 
Liver weight(% body weight) 4.2 ± 0.3' 4.8 ± 0.4' 4.1 ± 0.2' 
Energy intake (kJ/d) 502 ± 46 509 ± 24 480 ± 24 
Fat energy Intake (kJ/d) 176 ± 16' 361 ± 16' 34 1 ± 17' 
Creatine intake (glkg ·d) 3.1 ± 0.1 
Values are means ± SO, n- 6. Means in a row with superscripts without a common letter 
differ P < 0.05. 
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Table 4-2 
Liver total fat, triglycetides, cholesterol and TSARS, and plasma glucose and insulin in 
rats fed Control (C), high-fat (HF) or HF liquid diet with creatine (HFC) for 3 wk. 
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c HF HFC 
Liver Total Fat (mglg tissue) 66.1 ± 14.1' 102.4 ± 23.3 52.4 ± 12.0' 
Liver Triglycerides (J.IInol/g tissue) 22.5 ± 6.7' 42.2 ± 9.2' 16.6 ± 4.5' 
Liver Cholesterol (J.unol/g tissue) 4.9 ± 0.7' 6.1 ± 0.8' 4.9 ± 0.6' 
Plasma Glucose (mmol!L) 7.2 ± 1.4' 9.6 ± 1.7' 7.8 ± 1.2ab 
Plasma Insulin (pmoi/L) 82.8 ± 24. 1 97.4 ± 14.3 79.4 ± 20.7 
Liver TBARS (nmol/g tissue) 136 ± 2' 155 ± 16b 134 ± 10' 
Values are means± SD, n=6. Means in a row with superscripts without a common letter 
differ P < 0.05. 
117 
Figure 4.1 
Oil-red-O stained liver sections of rats fed Control (C), high-fat (HF), or HF liquid diet 
with creatine (HFC) for 3 wk. Values are means ± SO, n=3. Means without a common 
letter differ, P <0.05. 
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Table 4-3 
Plasma levels of creatine, GAA, homocysteine, and cysteine, and liver levels of SAM, 
SAH, and SAM:SA!-1 ratio in rats fed Control (C), high-fat (HF), or HF liquid diet with 
creatine (H FC) for 3 wk. 
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c HF HFC 
Plasma 
Creatine (mmoVL) 0.085 ± 0.0 19' 0.0934 ± 0.0 15' 0.995 ± 0.1 52' 
GAA (~moi/L) 5.1 ± 0.6' 6.1 ± 0.4' 1.7 ± 0.1 ' 
Hey (~tnoi!L) 6.4 ± 1.0 6.2 ± 1.0 5.0 ± 0.8 
Cysteine (mmol/L) 0.196 ± 0.015" 0.219 ± 0.01 2' 0.300 ± 0.026' 
Liver 
SAM (nmol/g tissue) 67.2 ± 6.3' 55.2 ± 5.4' 66.4 ± 7. 1' 
SAH (nmol/g tissue) 7.1 ± 1.1 7.9 ± 0.8 7.5 ± 0.5 
SAM:SAH 9.6 ± 0.8' 7.1 ± 0.8' 8.8 ± 0.7' 
Values are means ± SD, n- 6. Means in a row with superscripts without a common letter 
di!Ter P < 0.05. 
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As has been reported (49, 11 3), creatine supplementation led to decreased renal 
AGAT acti vity and concentration (Figure 4.2) and plasma GAA concentration in rats 
given creatine, compared to control rats and those on high fa t diet (Table 4-3). Creatine 
supplementation increased liver PE and decreased the PC/PE ratio compared to rats fed 
the other diets. There were no differences in PEMT mRNA expression among any of the 
groups (Table 4-4) . 
We examined the abundance of genes involved in the metabolism of S-containing 
amino acids, fatty acids and phospholipids. HF increased BHMTI , GNMT and MGA Tl 
expression. Creatine supplementation nonnalized to control levels the abundance of these 
genes. With regard to fatty acid metabolism, rats fed the HF diet had reduced PPARa 
mRNA levels as well as those of its downstream targets CPT I a and LCA D, genes of 
mitochondrial B-oxidation when compared to rats fed the other diets (Table 4-4). Creatine 
supp lementation nonnali zed the expression of these genes. Previously, Koonen et al. (94) 
showed that the hepatic express ion of CD36, a fatty acid transporter, alters the in vivo 
rate of fatty acid uptake and triglycerides storage in mice. In our study, CD36 was not 
affected by the high fat di et, but it was reduced in livers of creatine- supplemented rats 
when compared to control rats. The level of mRNA for VLCAD and UCP2 was not 
affected by these diets (data not shown) 
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Figure 4.2 
Renal AGA T protein and activity (A) , and hepatic content of phosphatidylcho line (PC), 
phosphatidylethanolamine (PE) and phosphatidylcholine/phosphatidylethanolamine 
ratio(B) in rats fed Control (C), high-fat (HF), or HF liquid diet with creatine (HFC) for 3 
wk. Values are means ± SD, n=6. Means in a row with superscripts without a common 
letter differ P < 0.05. 
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Table 4-4 
PEMT, PPARcx, CD36. CPT Ia, LCAD, BHMT. GNMT, and MGAT mRNA levels in rats 
fed Control (C), high-fat (HF), or HF liquid diet with creatine (HFC) for 3 wk. 
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c HF HFC 
mRNA 
PEMT 1.00 ± 0.14 1.00 ± 0.09 0.98 ± 0.17 
PPARcx 1.10 ± 029b 0.55 ± 022' 1.08 ± 0.29' 
CD36 1.01 ± 0.016' 0.85 ± 0.27' 0.52 ± 0.19' 
CPT Ia 0.82 ± 0.25' 0.44 ± 0.22' 0.83 ± 0.20' 
LCAD 1.04 ± 022b 0.55 ± 0.08' 0.88 ± 0.10' 
BHMT 0.64 ± 0.12' 1.20 ± 0.52' 0.54 ± 0.22' 
GNMT 1.00 ± 0.05' 1.73 ± 0.2' 0.88 ± 0.25' 
MGAT 1.01 ± 0.23' 1.64 ± 0.29' 0.96 ± 0.36' 
Values are relative mRNA expression, standardized to cyclophilin, glven as means ± SO, 
n=6. Means in a row with superscripts without a common Jetter differ P < 0.05. 
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4.5 Discuss ion 
The principal finding of the present study is that creatine supplementation 
prevented the hepatic fat accumulation that occurs upon feeding a high-fat diet to rats for 
three weeks. The effects of betaine supplementation on SAM availability and the 
prevention of fatty liver are well known (88, 90, 99). Previous studies have shown that 
betaine supplementation regulates phosphatidylcholine synthesis and normalizes VLDL 
production rates (88), thus preventing either high fat diet- or ethanol-induced fatty liver 
(10, 5 1, 88, 90, 99). PC biosynthesis is required for the nom1al secretion of VLDL by 
hepatocytes. Both the PEMT (81) and liver-specific CTa knockout mice (77) have 
impaired PC biosynthesis which leads to fatty liver. Furthennore, it has been shown that a 
dramatic reduction in the PC/PE ratio results in steatohepatitis and liver failure (104). To 
our knowledge, this is the first study that shows that creatine can exert such a protective 
effect. 
Creatine supplementation is known to modu late methylation demand ( 49) and 
decrease the plasma homocysteine concentration (43, 49), brought about by a remarkable 
(90%) down-regulation of renal AGAT enzyme activity. In the present study, creatine 
supplementation also caused a significant reduction in the plasma GAA concentration 
(Table 4-3) and, consequently, a reduction in the endogenous formation of creatine. 
Creatine supplementation also prevented the decrease in liver SAM concentration seen in 
HF-fed rats. SAM is required to fo nn several methylated compounds through 
transmethylation reactions (153), of which phosphatidylcholine synthesis and creatine 
synthesis are quantitatively the most prominent. Phospholipid methylation is thought to 
be the major SAM-consuming pathway, since hepatic phosphatidylcholine (PC) synthesis 
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by PEMT is responsible for approximately 50% of hepatic Hey fonnation (124). Creatine 
synthesis is also responsible for a very considerable consumption of hepatic SAM ( 153), 
perhaps as much as 40%. Because both PEMT and GAMT share the same hepatic SAM 
pool, we originally hypothesized that creatine supplementation could lead to a sparing 
effect on SAM utilization and result in increased PC fonnation. The increased hepatic 
SAM levels are consistent with such a sparing effect. However, PC levels and PEMT 
mRNA were unaltered by dietary treatment. Although creatine supplementation did 
increase PE and, consequently, resulted in a small decrease in the PC/PE ratio, it is 
unlikely that altered phospholipid metabolism plays an important role in either the 
development of steatosis in rats fed the H F diet or in its prevention by creatine. 
Nevertheless, we cannot rule out an increase in a key hepatic pool of PC that is not 
reflected in our measurements of total hepatic PC. We therefore examined the abundance 
of other key hepatic mRNA levels to see if they could shed light on how creatine 
supplementation might prevent fat accumulation. 
The HF diet reduced mRNA levels for PPARa as well as those of its downstream 
targets CPT Ia and LCAD. PPARa is essential in the modulation of lipid transport and 
metabolism, mainly through activating mitochondrial and peroxisomal fatty acid beta· 
oxidation pathways (1, 19). Carnitine palmitoyltransferase Ia (CPT! a) is a regulatory 
enzyme in mitochondrial f1-oxidation, and a target of PPARa (19, 53). LCAD, which is 
also a target of PPARa, catalyzes a key reaction in beta-oxidation (143). Creatine 
supplementation nonnalized these changes in mRNA levels. Creatine also reduced CD36 
mRNA levels (a fatty acid transporter). Together, these changes could provide a 
mechanism by which creatine reduces fat accumulation in the liver. Previous studies have 
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shown impaired fatty acid metabolism induced in rats fed a high-fat diet (I, 56, 154) as 
well as in NASH patients (12). In this regard, the findings of Ayoma et al. (7), that 
PPARa-null mice have both hepatic steatosis and decreased mRNA levels for proteins 
involved in fatty acid oxidation, are of particular relevance. Abdehncgeed et al. (I) also 
found severe steatosis, inflammation and increased parameters of oxidative stress in 
PPARa-nu\1 mice who were fed a high-fat diet for 3 weeks. These authors concluded that 
PPARa plays a critical role in preventing steatosis and fat-related oxidative stress and 
inflammation via effects on fatty acid catabolism (154). To the best of our knowledge, 
our study is the first to demonstrate the regulation of PPARa expression and its 
downstream targets by creatine. 
Feeding a high fat diet increased the hepatic abundance of mRNA for both BHMT 
and GNMT. These RNA abundances were nonnalized in creatine-supplemented rats. 
These results suggest that feeding high-fat diet may induce BHMT to promote 
remethylation of homocysteine, and GNMT to nonnalizc the hepatic SAM:SA I-I ratio. 
BHMT transfers a methyl group from betaine to homocysteine, to regenerate methionine. 
GNMT uses SAM to methylate glycine, producing sarcosine (N-methylglycine) which, 
via sarcosine dehydrogenase, is reconverted to glycine with the transfer of a one-carbon 
group to the mitochondrial folate pool. 
Creatine supplementation was at 3. 1 g/kg/day, which is appreciably higher than 
the 0.3 g/kg/day classically proposed for humans (66, 72). However, the 1% creatine 
supplemented diet was chosen because it has been previously shown to downregulate the 
renal L-arginine:glycine amidinotransferase (49) and decrease plasma Hey concentration 
(43, 152) in rats. It should be recognized that allometric scaling factors must be taken into 
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account when comparing doses between animals of different sizes . In general, mass-
specific metabolic rate scales as the 0.75 exponent of mass. Therefo re, a 300 g rat has 
approximately four times the mass-specific metabolic rate of a 70 kg human. When 
expressed on thi s physiological basis, the rats received approximately 2.5-fold the 
creatine supplementation recommended fo r humans. 
In conclusion, creatine supplementation prevented fatt y li ver induced by 3 weeks 
of a high-fat diet in rats. This is the first study that shows thi s protecti ve effect of 
creatine. This effect is not totall y ex plained by modulation of meth yl balance and 
consequent increased SAM avail ability, the explanation for the known effect of betaine 
on fatty li ver. Our results do suggest that creatine supplementation also nom1ali zed some 
enzymes of methionine metabolism. In addition, and cri ticall y, creatine supplementation 
nonnali zed the expression of PPARaas well as its downstream targets, CPT\ and LCAD, 
genes that code for key mitochondrial enzymes of beta oxidation. Since the expression of 
these genes were decreased by the high-fat di et, their nom1ali zation suggests a possible 
mechanism by which creatine may prevent liver fat accumulation. Further studies are 
necessary to elucidate the exact mechanisms by which creatine supplementation 
modulates the expression of PPARa. 
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Chapter 5 
The Effect of Portacaval Anastomosis on the Expression of Glutamine Synthetase and 
Ornithine Aminotransferase in Perivenous Hepatocytes 
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The author appreciates that the study conducted in the following chapter is not directly 
related to the topics addressed in the three preceding chapters. Nevertheless, it is 
intimately related to the field of hepatic amino acid metabolism which encompasses the 
creatine studies. In fact chapter 5 represents the first study undertaken during my PhD 
research. However, the focus of the laboratory changed to creatine due to grant funding 
exigencies. For this reason the remaining studies dealt with creat ine metabolism. 
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5.1 Abstract 
There is functional zonation of metabolism across the liver acinus, with glutamine 
synthetase restricted to a narrow band of cells around the tern1inal hepatic venules. 
Portacaval anastomosis, where there is a major rerouting of portal blood flow from the 
portal vein directly to the vena cava bypassing the liver, has been reported to result in a 
marked decrease in the activity of glutamine synthetase. It is not known whether this 
represents a loss of perivenous hepatocytes or whether there is a specific Joss of 
glutamine synthetase. To answer this question, we have determined the activity of 
glutamine synthetase and of another enzyme from the perivenous compartment, ornith ine 
aminotransferase, as well as the immunochemical localization of both glutamine 
synthetase and ornithine aminotransferase in rats with a portacaval shunt. We have also 
determined the expression of a perivenous ammonium transporter, RhBG, in these 
animals. Portacaval shunt caused a marked decrease in glutamine synthetase activity and 
an increase in ornithine aminotransferase activi ty. Immunohistochemical analysis showed 
that the glutamine synthetase and ornithine aminotransferase proteins maintained their 
location in the perivenous cell s; the mRNA concentration for RhBG remained 
unchanged. These results indicate that there is no generalized loss of perivenous 
hepatocytes but rather a significant rearrangement in expression of these proteins and 
hence metabolism in this cell population. 
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5.2 Introduction 
The functional zonation of metabolism across the hepatic acinus is well 
established (61, 86, 100). This phenomenon is attributed both to differences in the 
composition of blood as it travels from the portal triad to the central vein and to the 
differential expression of proteins in different regions of the acini. Acini are microscopic 
structures containing cells that are provided with blood from the branches of the two 
afferent vessels {the portal vein and the hepatic artery) and drained by the efferent vessel 
{hepatic vein). Cells nearest the portal triad (periportal) have the first opportunity to take 
up molecules and hormones from portal venous and arterial plasma whi le cells nearest 
the hepatic vein (perivenous) are presented with blood that is relatively depleted in 
oxygen and some honnones and may be enriched in metabolites produced in periportal 
cells. The differential expression of such functional molecules as enzymes, transporters 
and receptors across the acinus has been well documented (85). Several metabolic 
processes have been localized to discrete regions of the acinus; it is known that periportal 
cells primarily oxidize fatty acids and some amino acids while performing 
gluconeogenesis and ureagenesis whereas perivenous cells primarily oxidize glucose, 
perfonn lipogenesis and synthesize glutamine (84). 
The zonation of nitrogen metabolism across the hepatic acinus is particularly 
striking. Ammonia arising from amino acid catabolism in enterocytes and that provided 
by the metabolism of intestinal microflora is largely converted to urea in the periportal 
region of the acini; ammonia that escapes conversion to urea is largely converted to 
glutamine in the perivenous hcpatocytes (84). Studies using immunohistochemical and in 
situ hybridization techniques have indicated that glutaminase and the enzymes of urea 
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synthesis are locali zed exclusively to periportal cell s (1 17), while glutamine synthetase 
(GS) has been localized to a 1-3 cell layer of perivenous hepatocytes (60, 6 1, 149, 165, 
166). The di fferential locali zation of glutaminase and glutamine synthetase supports the 
idea of simultaneous glutamine synthesis and catabolism in the liver (180). Glutaminase, 
in the periportal cell s ( 11 7) provides ammonia from glutamine to the urea cycle, while 
the synthesis of glutamine in the peri venous cells functions as a 'scavenging' system for 
excess ammonia ( 179). Consistent with thi s idea is the finding that the system N 
transporter that is partially responsible fo r glutamine uptake is found in periportal cells 
(30) while the SLC IA2 and SLC IA4 proteins (20) and system G transporter activity 
responsible for glutamate uptake arc found primarily in perivenous cell s ( 157). The 
RhBG transporter, necessary for providing ammonium for glutamine synthesis, has also 
been locali zed to perivenous cell s in the li ver (18 1, 182). 
In li ver di seases that result in fibrosis and portal hypertension, angiogenesis can 
result in the shunting of blood from the portal vein to the systemic circul ation; thi s is 
referred to as portacaval anastomosis. In human liver cirrhosis, the surgical shunting of 
portal blood relieves backpressure and prevents fu rther organ and vascular damage ( 13 7, 
138). Among the major complications of cirrhosis and portacaval anastomosis are 
hyperammonemia and hepatic encephalopathy ( 127). Shunting of portal blood around the 
li ver will result in marked changes in the composition of arteri al blood; in addition, 
portacaval anastomosis results in altered expression of some proteins, presumably 
because of alterations in metabolite and hormone concentrations. Rats with surgical 
port acaval anastomosis show up to 90% reduction in glutamine synthetase acti vity (62). 
In addi tion, the GS protein is onl y fai ntl y detected in humans with fib roti c li ver di sease 
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(13 1). However, it is not known whether there is generalized loss of perivenous cell 
function in portacaval anastomosis or there is simply a down-regulation of glutamine 
synthetase expression. Other enzymes such as ornithine aminotransferase (OAT), which 
are localized to the same perivenous cell population as glutamine synthetase (98), have 
not been examined under such conditions. The goal of this study was to determine 
whether peri venous cell function is lost in portacaval anastomosis. We demonstrate that 
there is a marked loss of glutamine synthetase together with an increased expression of 
hepatic OAT in rats with portacaval anastomosis and that these activities remain 
restricted to a small band of cells at the central venous terminus of the acinus. This 
indicates that there is a specific loss of glutamine synthetase, rather than a generalized 
loss of perivenous cell function in portacaval anastomosis. 
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5.3 Materials and Methods 
Reagents: All reagents were obtained from Sigma-Aldrich (Missouri, USA) unless 
otherwise indicated. Ferric chloride was obtained from Fisher Scientific (New Jersey, 
USA). Sodium pentobarbital was obtained from Ceva Sante Animale (Libourne Cedex 
France). 
Animals: Male Sprague-Dawley rats were obtained from Charles River, Montreal. All 
portacaval shunt and sham surgical procedures were perfonned by Charles River, about 2 
weeks before the animals were shipped to Memorial University of Newfoundland. All 
procedures were approved by Memorial University of Newfoundland Institutional 
Animal Care Committee (IACC) and were in accordance with the guidelines set by the 
Canadian Council of Animal Care (CCAC). 
Experimenta l Model: Animals were maintained in metabolic cages for two weeks on a 
12: 12 hour light:dark cycle in a temperature-controlled environment (20°C). They were 
fed a rodent chow diet containing 20% crude protein (Purina 5001 Rodent Chow). Sham-
operated rats were pair-fed to the shunted rats who were allowed to eat ad libitum. Body 
weight was measured every three days. On the morning of the experiment, rats were 
anaesthetized with sodium pentobarbital (65 mglkg body weight, i.p.). Samples of blood 
were taken from the abdominal aorta into heparinized syringes and placed on icc for a 
few minutes while liver tissue was taken. A piece of liver for RNA analysis was 
immediately freeze-clamped with aluminum tongs, pre-cooled in liquid nitrogen. Other 
pieces of liver were quickly taken for enzyme assays. 
Enzyme Assays: Glutamine synthetase (GS) was measured by the method of Vorhaben 
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et al. ( 170). Ornithine aminotransferase (OAT) was assayed using the method of Knox 
and Hcnfeld (71 ). Arginase was assayed by measuring the urea produced by reaction 
with thiosemicarbazide, using the method previously described by Schimke (142). All 
assays were carried out at 3 7°C and were shown to be linear with time and protein under 
the conditions employed. 
Plasma Amino Acid Analysis: Arterial blood was centrifuged at 3,000 x g for 15 min 
and plasma was removed with a Pasteur pipette. 0.4 mL aliquots of plasma were added to 
0.1 mL of 10% sulfosalicylic acid and allowed to sit on icc for 30 mins, at which time 0.3 
mL of Lithium Citrate Sample Dilution Buffer pH 2.2 (Beckman Coulter) was added. 
Samples were mixed thoroughly and centrifuged at 10,000 x g for 5 mins. The 
supematant was removed and amino acids were analy-t:ed using a Beckman 121 MB 
amino acid analyzer with a Benson 0-X 0.25 cation exchange column and a single-
column three buffer lithium method. 
Immunohistochemistry: Liver sections were prepared as follows. A small piece of liver 
tissue was rinsed in saline and placed in 4% phosphate-buffered fo rmaldehyde and 
shaken gently. Samples were allowed to fix at 4°C for 24 hours at which point they were 
embedded in paraffin blocks. Four 5 J.Lm-thick sections were cut using a cryostat 
(Microm, Francheville, France) and placed on glass slides (ChemMate, Dako). Slices 
were deparaffinized with two 15 min washes with xylene at room temperature, step-
rehydrated with two 5 min washes in I 00% ethanol and two 5 min washes in 95% 
ethanol, followed by one 10 min wash in 70% ethanol, and, finally, two 5 min washes in 
doubly-distilled water. Non-specific sites were coated by incubating for 2 hours in 
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phosphate-buffered saline (PBS: 10 mM phosphate buffer, 150 mM NaCI, 10 mM KCI 
pH 7.4) supplemented with 0.05% NaN3, 0.3% Triton X- 100, 1% bovine serum albumin 
(BSA) (Sigma) and I% goat serum (DAKO). Slides were rinsed by means of three IS 
min washes in PBS and were incubated at 4-8 "c with rabbit polyclonal OAT antibody 
(1:75 dilution (1 03) mouse monoclonal glutamine synthetase antibody (dilution 1:75) 
(Chemicon International, Temecula, CA) in PBS supplemented with 0.05% NaN3, 0.3% 
Triton X- 100, 1% BSA. Sections underwent three 15 min washes with the same buffer 
(without antibody). Alexa-conjugated antibodies were centrifuged at 10,000 x g for 2 min 
before use. For confocal microscopy, sections were incubated for 60 min at room 
temperature in the dark with PBS containing 0.5% gelatin and Alexa 488-conjugated 
affinity-puri fied goat anti-rabbit (dilution 1 :300) and Alexa 633-conj ugated affinity-
purified goat anti-mouse (dilution I :300, Jackson Laboratories Inc, USA). Sections were 
washed for two hours in the same buffer. Slices were counterstained for 3 mins with 2 
p.g/mL Hoechst stain (Polysciences Inc. USA). Sections were washed for 2-6 hrs in PBS 
and mounted with Fluoprep (Biomerieux, France). Images were taken with a Leica 
confocal system TCS-SP2 (oil immersion objective: x 63 magnification), using a fil ter set 
at 505-559 nm for Alexa 488 {OAT protein), 678-768 nm for Alexa 633 (glutamine 
synthetase protein) and 403-496 nm (Hoechst). Photographs were anaiy-.::ed using a Leica 
(DMR, Gennany) microscope equipped with a color video camera (Kodak DC290 digital 
zoom) coupled to a computer (MacOS 9.2). All data were analyzed using the Image J 
software. Pictures from confocal microscopy were analyzed and merged using Image J 
software and transferred to Adobe Photoshop CS3 extended version. 
Scmi-quantitivc PCR : Total RNA was prepared from freeze-clamped livers by a rapid 
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guanidinium thiocyanate method (35). 2 p.g of RNA was reverse transcribed using a one 
step reverse transcription kit (Qiagen; Mississauga, ON, Canada) and amplified by 30 
cycles. An upstream primer (5'-CTCCTCTTTGCGATCTTTG-3') and a downstream 
primer (5'-CCATGGAAAGAGTGGAGGAA-3') were designed for rat ammonia 
transporter RhBG sequence (Genbank Accession NM_\83054). Primers were designed 
to amplify a 267-bp fragment (Invitrogen; Burlington, ON, Canada). A 768-bp fragment 
of rat .6-actin gene was co-ampli fied using amplimer set primers. PC R products were 
separated on a 2% agarose gel. Ethidium bromide (Biorad; Mississauga, ON, Canada) 
stained gels were visuali zed by UV ill umination (using Chemilmager 4000) and 
quantified by densitometry, using Alphaeasc software (Al pha lnnotech, San Leandro, 
CA). The integrated dens ity values for RhBG were normali zed to those of ,B-act in to give 
the relative expression. 
Statistical Analys is: Enzyme activity, plasma amino acid and Integrated Density Values 
from the RNA analysis were all analyzed using a Student t-test in Prism Graph Pad 
software version 3.02. All values are reported as the mean ± standard deviation. 
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5.4 Results 
The body weights of the shunted rats were significantly lower when they were 
received approximately two weeks post surgery, than were the sham-operated animals. 
This is probably because both groups were fed ad libitum until the rats had arrived at 
Memorial University, at which point the sham-operated rats were pair-fed according to 
the shunted rats' intake. When all rats were receiving the same amount of food, the 
shunted rats gained weight more quickly than the sham-operated groups so that their 
weights were not different from the sham-operated rats after 14 days of pair-feeding. 
Sham-operated control and Shunted animals weighed 354.5 ± 24.2 g and 345.0 ± 37.4 g, 
respectively on the day of tissue sampling. 
Glutamine synthetase activity was significantly lower in the shunted rats, being 
only 16% of that found in sham operated rats (Figure 5.Ja). However, ornithine 
aminotransferase activity was significantly higher in the shunted rats, being 170% of that 
found in the sham-operated animals (Figure 5.1b). We also assayed arginase, which is 
expressed in the periportal region of hepatic acini. There was no significant difference in 
arginase activity between the groups (Figure 5. \c). 
The relative integrated density values for the mR A of the ammonium transporter 
RhBG were not significantly different between the groups (Figure 5.2). Since this 
transporter is exclusively restricted to the perivenous hepatocytes, its unchanged 
expression is also consistent with the notion that perivenous hepatocytes are not lost upon 
portacaval anastomosis. 
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Figure 5. 1 
Enzyme activities for glutamine synthetase, ornithine aminotransferase and arginase in 
liver. Activity is given as nmol/min/mg protein and values arc expressed as means ± 
standard deviations. P < 0.05 was taken as significant, n = 6 
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Figure 5.2 
Expression ofRhBG mRNA in li ver. Values are expressed as means± standard deviation 
in arbitrary units and all groups were nonnalized to sham-operated control values. P < 
0.05 is taken as signi ficant , n = 3 
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Confocal microscopy (Figures 5.3) confirmed the perivenous co-locali zation of glutamine 
synthetase and ornithine aminotransferase proteins. Shunted animals showed a marked 
drop in glutamine synthetase fluorescence and a marked increase in OAT fluorescence 
compared to the sham-operated rats. 
Plasma amino acid analysis, given in Table 5- l , showed significant increases in 
glutamine, asparagine, histidine, phenylalanine and tyrosine and a significant decrease in 
threonine in the shunted rats compared to the sham-operated rats . 
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Figure 5.3 
Confocal fluorescence microscopy of liver sections. Pictures a-c correspond to the sham-
operated rats while d-f correspond to shunted rats. a and d show GS (red), b and e show 
OAT (green), and c and f show the overlay with nuclei stained (blue). White bar is 100 
11m in length 
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Table 5-1 
Plasma amino acids from sham-operated contro l rats and rats with portacaval shunts. 
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Sham-operated Shunted 
Amino Acid nmol/mL nmol/mL 
Proline 177.3 ± 41.9 209.5 ± 43.0 
Ornithine 59.7 ± 11.2 81.5 ± 33.5 
Arginine 150.6 ± 26.5 175.5 ± 51.8 
Citruline 79.4 ± 17.4 86.6 ± 12.6 
Glutamine 495.1 ± 44.7 691.5 ± 11 4.7' 
Glutamic acid 88.5 ± 13.4 82.5 ± 12.7 
Aspartic acid 12.2 ± 2.1 16.0 ± 2.5 
Asparagine 41.4 ± 8.2 84.6 ± 16.7' 
Alanine 373.8 ± 36.4 469.4 ± 93.0 
Glycine 237.9 ± 34.5 279.7± 38.9 
Serine 200.1 ± 7. 1 215.3 ± 31.7 
Methionine 51.3 ± 6.5 59.9 ± 12.9 
Taurine 187.7 ± 37.4 152.2 ± 4.5 
Histidine 63.3 ± 10.2 I 00.6 ± 17.2' 
Threonine 194.2 ± 22.2 127.3 ± 26.5' 
Lysine 362.0 ± 63.6 363.9 ± 52.5 
Leucine 124.1 ± 12.4 103.1 ± 14.3 
Isoleucine 73. 1 ± 9.9 58.3 ± 5.5 
Valine 174.4 ± 17.6 150.4 ± 14.9 
Phenylalanine 61.5 ± 3.6 13 1.0 ± 19. 1' 
Tyrosine 83.3 ± 4.7 137.6 ± 24.7' 
Tryptophan 58.8 ± 15.5 71.7 ± 10.9 
Note: All values arc expressed as the mean ± standard deviation. P < 0.05 was taken as 
significant and indicated by an asterisk, n = 6. 
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5.5 Discussion 
The key question addressed in this study is whether or not perivenous cells are 
destroyed when animals undergo a portacaval anastomosis. As previously demonstrated 
by Girard and Butterworth (62) animals with portacaval anastomosis lose up to 90% of 
glutamine synthetase activity. Although nom1al hepatic zonation, with perivenous 
glutamine synthetase, is retained in human hepatic fibrosis, glutamine synthetase was 
undetectable in cirrhotic nodules ( 131 ). There are two possible explanations for the loss 
of glutamine synthetase in rats with portacaval anastomosis: as a result of the selective 
Joss of perivenous hepatocytes, as suggested by Butterworth's group (45, 62), or a 
specific loss of expression of glutamine synthetase by these cells. In order to address this 
question we examined the expression of two other genes known to be selectively 
expressed in perivenous hcpatocytes. 
Hepatic ornithine aminotransferase activity was not decreased by the portacaval 
shunt. In fact it increased in activity. More importantly, its expression remained limited to 
a small rim of hepatocytes around the centrilobular veins, exactly as seen in the sham-
operated control animals. The same population of perivenous hepatocytes also expresses 
the ammonium transporter, RhBG, in perivenous hcpatocytes. Although the lack of 
suitable antibody prevented us from carrying out an immunohistochemical study of its 
location, its mRNA expression remained unchanged in the livers of portacaval shunted 
rats. It is clear, therefore, that portacaval shunting brings about a specific loss of 
glutamine synthetase, and not of the perivenous hepatocytes. 
It is of interest to compare the hepatic expression of these two enzymes of amino 
acid metabolism, glutamine synthetase and ornithine aminotransferase, with the relevant 
153 
amino acid levels. Plasma glutamine and asparagine levels were significantly increased in 
the shunted rats. It has been established that there is an induction of glutamine synthetase 
in the muscles of shunted rats (62) and we consider it likely that the increase in plasma 
glutamine that we found in the shunted rats is, at least in part, due to increased muscle 
glutamine synthesis. Synthesis of glutamine and asparagine in muscle would also be 
facilitated by elevated circulating ammonia concentrations seen in animals with 
portacaval shunt. 
There was no significant difference between ornithine levels in the shunted rats 
and the sham-operated controls, despite an elevated activity of omithine aminotransferase 
per gram liver in the shunted rats. Since the hepatic mass is markedly less in the 
portacaval shunted rats (approximately 50% of control), the ornithine aminotransferase, 
expressed per rat is not increased. In addition, total hepatic blood flow is decreased by 
approximately 40% in such animals ( 14). Therefore the greater OAT expressed per gram 
of liver tissue may simply offset the loss in total hepatic mass and reduced blood flow. 
Immunohistochemistry of both enzyn1es showed that total protein amount 
reflected the changes in enzyme activity and confim1ed the exclusive localization of these 
proteins to the perivenous cells of liver acini. RhBG expression did not show the same 
down-regulation as glutamine synthetase which suggests that ammonia is sti ll capable of 
uptake by the perivenous cells. We therefore conclude that there is not a generalized loss 
o f perivenous cell function; rather, there are significant changes in the expression of these 
two enzymes in this cell population. 
The primary focus of this study was whether or not perivenous hepatocytes are 
lost in rats with portacaval shunts. We did not address the mechanism whereby the 
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expression of glutamine synthetase is decreased. Nevertheless, some comment on this 
issue is appropriate. Desjardins et a!. (45) have found that the decrease in hepatic 
glutamine synthetase activity and protein content in the livers of portacaval shunted rats 
is accompanied by a comparable decrease in its mRNA level, suggesting an effect at the 
level of gene expression. Cadoret et al. (33) have shown that P-catcnin signaling in the 
absence of APC action induces the expression of a number of perivenous-expressed 
genes, such as glutamine synthetase, ornithine aminotransferase and the glutamate 
transporter GLT- 1. However, since ornithine aminotransferase activity is increased, 
rather than decreased, in the portacaval shunted rats, impaired P-catenin signaling cannot 
be invoked to explain the decreased expression of glutamine synthetase. It has been 
shown that normal hepatic architecture, rather than the supply of portal blood, is critical 
for glutamine synthetase induction in liver cells (58, 59). These studies suggest a cell-cell 
interaction hypothesis, in which the proximity of the perivenous cells to the endothelium 
is a critical factor in the expression of glutamine synthetase. 
A number of physiological and pathological parameters are known to affect 
hepatic glutamine synthetase activity. There is some evidence that the expression of 
glutamine synthetase in the liver is controlled by oxygen tension. Glutamine synthetase is 
up-regulated under low oxygen tension and is returned to nom1al levels when oxygen 
tension is improved (1 29). This is not likely to play a role in our rats four weeks after 
portacaval anastomosis. It has been shown that hepatic oxygen tension and effective 
blood flow are significantly lower in surgical portacaval anastomosis immediately after 
surgery but oxygen tension is returned to normal after one week while blood flow 
remains low (14 1). In addition, studies by HaUssinger et al. have shown that glutamine 
155 
synthetase is sensitive to inhibition by nitric oxide by virtue of nitration of a key tyrosyl 
residue at its active s ite (63). In this situation, glutamine synthetase activity is decreased 
by 50% but glutamine synthetase protein is only decreased by 20%. This mechanism, 
however, cannot account for the loss of glutamine synthetase activity in the shunted 
animals since this appears to be brought about by decreased expression of glutamine 
synthetase messenger mRNA (45). 
Honnonal regulation of glutamine synthetase may be at play in rats with 
portacaval anastomosis. Plasma glucagon levels are markedly elevated in rats with 
portacaval anastomosis (II ). There is very good evidence that glucagon increases the 
activity of ornithine aminotransferase in vivo ( 122) and some evidence that glucagon may 
decrease glutamine synthetase activity in the liver (70). 
In conclusion, our experiments clearly point to a specific loss of glutamine 
synthetase expression, rather than a generalized loss of perivenous hepatocytes in 
portacaval anastomosis. This appears to be brought about by a relatively specific 
alteration in the regulation of glutamine synthetase expression. Further studies that 
address this mechanism are warranted. In addition, it will be of interest to detennine 
whether a similar phenomenon occurs in humans. 
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Chapter 6 
General Discussion 
and Concluding Remarks 
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6.1.0 C reatine Biosynthesis in the Liver and Pancreas 
6.1.1 Hepatic Creatine Synthesis 
In the first paper we set out to investigate creatine synthesis in the liver. We 
wished to characterize the activity of GAMT in hepatocytes and detennine if it is 
regulated by dietary creatine. In addition we had postulated that there may be AGAT 
activity present in the liver; this was based on a number of pieces of infonnation and a 
consideration of whether arginine from the urea cycle could be used to synthesize 
creatine. Three pieces of evidence supported our hypothesis regarding hepatic AGA T 
activity in the rat. Firstly, AGAT activity is cited in the livers of other mammals such as 
human, monkey and pig in a review by Wyss and Kaddurah-Daouk (186). Secondly, 
AGAT protein was detected in rat liver using immunohistochemistry (112). Lastly, there 
is a complication with the traditional enzyme assay for the AGA T enzyme. The assay is 
based on measuring omithine that is produced in a one-to-one mole ratio with GAA by 
the AGAT enzyme. The problem arises from the large activity of arginase in the liver. 
Arginase converts arginine provided in the assay medium into urea and ornithine and so 
the backb'TOund is extraordinarily high making it impossible to measure AGAT in this 
manner. Therefore the activity of AGAT in rat liver may have escaped detection in the 
past. Taken together these pieces of evidence suggested a potential for GAA synthesis in 
the liver. 
We were not able to detect AGAT activity in rat liver using HPLC to quantify 
GAA directly. We also incubated hepatocytes with 15N-ammonium (M+ l) chloride and 
were unable to measure either M+ l or M+2 creatine and therefore we must conclude that 
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arginine derived from the urea cycle is not used for creatine synthesis in rat liver. On the 
other hand, significant activity of GAMT was detected in rat liver and there was 
significant methylation of GAA in isolated hepatocyte incubations. The methylation of 
GAA by hepatocytes is dependent on the external concentrations of GAA provided in the 
incubation medium consistent with the known kinetics of the GAMT enzyme (126). Our 
findings are consistent with the notion that creatine synthesis in rat li ver is limited to the 
methylation of GAA that is synthesized in extra-hepatic tissue. This work supports the 
idea of methylation demand in which the rate of methylation is dictated by the 
concentration of methyl-accepting substrates. 
Isolated hepatocytes incubated in the presence of GAA and methionine showed an 
increased production of creatine compared to isolated hepatocytes incubated with GAA 
alone. This finding suggests that methylation in the liver can be influenced by the 
concentration of methionine that is presented to this organ. The presence of methionine in 
the incubations of isolated hepatocytes resulted in an elevation of the SAM concentration 
in these cells. The liver expresses the methionine adenosyltransferasc (MA TV! II} enzyme 
which converts methionine and ATP into SAM and pyrophosphate. The MATUIII 
enzyme nonnally occurs as a tetramer of subnunits and responds to increased 
concentrations of SAM by splitting into a dimer that is more active than the tetramer (32) 
and so is regulated by feed-back activation. The influence of methionine on MAT activity 
and SAM production suggests that dietary methionine may influence methylation in the 
liver. 
Provision of dietary creatine supplementation did not affect GAMT activity in the 
liver. Our data point to GAMT in the liver as being a slave to GAA concentrations in the 
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plasma. We know from previous studies that AGAT activity in the kidney is dramatically 
down-regulated by dietary creatine supplementation (113, 161) and the plasma GAA 
concentration is also dramatically lower in creatine supplemented rats (49, 152). We have 
also detennined that there was a significant uptake of GAA across the liver in vivo in rats 
fed diets free of creatine. Using the data collected we were able to make calculations 
relating to the capacity of the liver for creatine synthesis (methylation of GAA only) and 
we have found that the liver is capable of synthesizing a quantity of creatine sufficient to 
replace the amount of creatine that is lost per day. From this we infer that the regulation 
of creatine synthesis by creatine itself does not occur in the liver but via a reduction of 
AGA T activity in the kidney which in tum causes a reduction in plasma GAA and thus 
less GAA is taken up by the liver for methylation. 
6.1.2 Pancreatic C reatine Synthesis 
In chapter 3, I present a paper on creatine synthesis by pancreatic acini and the 
regulation of creatine synthesis in the pancreas. The enzymes for creatine synthesis had 
been detected in the pancreas many years ago ( 162), but the role that these enzymes serve 
in this tissue is yet to be determined. AGAT activity has been immunohistochemically 
localized to the acini in the pancreas (150) and therefore we isolated these cells in order 
to examine their ability to produce creatine. Since renal AGAT activity is dramatically 
down-regulated when creatine is supplemented in the diet ( 11 3), the regulation of 
pancreatic AGAT by dietary supplementation with creatine was also examined. The data 
show that the pancreas can indeed make modest amounts of both GAA and creatine. In 
addition, the regulation of pancreatic AGAT is not achieved in the same way as renal 
AGAT. 
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Pancreatic acini arc capable of producing both GAA and creatine from arginine, 
glycine and methionine. However, AGAT activity and the capacity for GAA synthesis 
were considerably higher in the pancreatic acini than the GAMT activity and the capacity 
for GAA methylation. Enzyme activies for the creatine synthetic enzymes in pancreatic 
acini were in line with previously reported activities in this tissue (162), with 
significantly Jess GAMT than AGAT activity. In addition, the synthesis of GAA under 
supraphysiological substrate concentrations was considerably higher than was the 
synthesis of creatine. So the fact that the capacity for GAA synthesis outstrips that of 
creatine synthesis in the pancreatic acini leaves the possibility that the pancreas is 
producing more GAA than creatine. GAA released by the pancreas could be taken up and 
methylated in the liver to fom1 creatine. Based on incubations of pancreatic acini with 
physiological concentrations of the amino acids, I have calculated that the whole rat 
pancreas could synthesize approximately 4% of the creatine required per day while GAA 
synthesis (when converted to creatine) would amount to an additional 8% of the creatine 
required per day. Thus, all together the rat pancreas could contribute up to 12% to total 
body creatine synthesis. However, the rat kidney is capable of synthesizing all of the 
GAA required per day ( 49) and the rat liver can methylate enough GAA to replace the 
creatine that is required per day (39), possibly making pancreatic creatine synthesis 
redundant. Observing this from a purely Darwinian perspective, one might ask whether 
the expression of the creatine synthetic enzymes in pancreatic cells has some benefit or 
whether they were useful at some earlier stage of evolution and have since become 
superfluous. Then again, from a developmental perspective, the enzymes for creatine 
synthesis may be important in early development and later become unnecessary. Indeed, 
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the expression of AGAT, GAMT and CRT I all change in rats throughout embryogenesis 
with AGA T not being expressed in the kidney until 18.5 days while pancreatic AGAT 
expression is present at 15 days of embryogenesis (23). One need only look at the results 
of deficiencies of the enzymes and transporter involved in creatine synthesis to 
understand the important role that creatine plays in brain and neural development (144) 
as all of the afflicted subjects display serious neuromuscular symptoms and mental 
retardation. Creatine may indeed play an important role in the secretion of hormones 
from the endocrine pancreas (96) and there is good evidence that the creatine kinase 
system affects insulin secretion from the P-cells (146). 
Both GAA and creatine could have a functional role in the pancreas. There has 
been a study in which relatively high concentrations of GAA and creatine stimulate the 
release of glucagon and insulin from pancreatic islets ( 11 0). It is not known how these 
compounds bring about the increased release of hormones from the pancreatic islets. 
Activity of creatine kinase has been detected in mouse pancreatic islets (128) and in our 
study we show that creatine supplementation significantly increases creatine phosphate 
levels in the pancreas (Table 3-2). An increase in the ATP:ADP ratio in pancreatic P-cells 
leads to increased insulin release (42, 146). 
The paper presented in chapter 3 also provides evidence that the regulation of 
pancreatic and renal AGA T by dietary creatine does not involve the same mechanism. 
McGuire et al. showed quite convincingly that renal AGAT is regulated by dietary 
creatine at the pre-translational level (113). The data from McGuire eta\. and from figure 
3.2 revealed reduced levels of mRNA and protein for the AGAT enzyme in kidneys of 
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rats fed creatine-supplemented diets. Figure 3. 1 clearly shows that dietary creatine does 
not affect AGAT mRNA or protein levels in the pancreas. There was however a modest 
reduction in pancreatic AGAT acti vity, which implies that there are two different types of 
regulation that affect AGAT. Creatine itself is not known to have a regulatory effect on 
the AGA T enzyme ( 186) and it is impossible to detem1ine what mechanisms are at play 
in the pancreas. Nevertheless this is an interesting observation and the retention of 
pancreatic AGAT expression may indicate the significance of GAA and creatine 
synthesis in the pancreas. 
6.1.3 NAFLD: Hepatic Fat Accumulation and Creatine 
Consumption of a high fat diet leads to the accumulation of triglycerides in the 
liver and to insulin resistance (34, 190). Accumulation of excess fat in lipid droplets in 
the liver is referred to as the "first hit" in the "Two·hit" model of NAFLD progression. 
The "second hit" includes increased lipid peroxidation and increased production of 
cytokines resulting in increased inflammation (41, 160). Impaired methionine metabolism 
has been observed in a number of different inflammatory liver diseases including 
NAFLD. NASH and alcoholic steatohepatitis (ASH) (8). Methyl-donors such as SAM 
and betaine have been used successfully to treat NAFLD (34). Betaine supplementation 
has been shown to dramatically elevate hepatic SAM levels in animals with NAFLD 
caused by consumption of a high fat diet (99). Through the action of BHMT, betaine is 
used fOr the remethylation of homocysteine. It has been postulated that increased 
availability of SAM allows for increased methylation of PE via the enzyme PEMT. The 
product of PE methylation is PC which is a phospholipid involved in the packaging and 
export of VLDL. PEMr-'· mice have been shown to have impaired export oftriglycerides 
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from the liver and so it appears that PC made via PEMT is important for nonnal 
packaging of VLDL ( 105). Thus increased PC facilitates the removal of lipids from the 
liver. 
The paper in Chapter 4 provides evidence that the accumulation of fat in the liver 
of rats fed high-fat diets is ameliorated by provision of creatine in the diet. Creatine is not 
a methyl donor; however the conversion of guanidinoacetate to creatine is a methylation 
reaction catalyzed by GAMT. We observe that the enzyme responsible for GAA 
synthesis as well as GAA itself is reduced when creatine is supplemented in the diet. It is 
also known that the methylation of GAA in the liver is proportional to the amount of 
substrate present in the circulation (Chapters 2 and 3) (39). Thus one might postulate that 
the down-regulation of creatine synthesis might spare SAM making it available for other 
methylation reactions. The data did show that creatine supplementation nonnalized SAM 
levels in rats fed the high-fat diet and so this is consistent with the idea that SAM is 
spared in the liver. However, there was no measurable increase in hepatic PC content nor 
was there a difference in the PEIPC ratio in the creatine-supplemented high-fat group, 
suggesting that the creatine supplementation did not alter PC metabolism in this case. It is 
important to point out that we did not measure flux of PC in the liver or the rate of 
oxidation of lipids in the liver, nor was VLDL secretion detcnnincd and so it is 
impossible to detem1ine if creatine truly affects these parameters in the rats fed high fat 
diets using the present data. 
Creatine appears to have beneficial effects in NAFLD in that it nonnalized the 
expression of genes that are altered by the consumption of high-fat diets. The expression 
of PPARa and its downstream targets CPT Ia and LCAD are down-regulated in the livers 
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of rats fed high-fat diets. This suggests that in the high-fat fed animals triglyceride 
synthesis would be favored over P-oxidation. Creatine supplementation prevented this 
fall in PPARa, CPTia and LCAD. Creatine supplementation also reduced CD36 
expression in the liver of rats fed the high-fat diets. CD36 is a key protein involved in the 
uptake of free fatty acids from circulation and has been associated with increased 
steatosis, hypcrinsulinemia, and insulin resistance in NAFLD, NASH and ASH (116). In 
fact, induction ofCD36 in the liver via activation of the nuclear receptors liver X receptor 
(LXR), pregnane X receptor (PXR) and peroxisome proliferator agonist receptor gamma 
(PPARy) results in hepatic steatosis which is absent in CD36 null mice (192). So it 
appears that creatine supplementation has two beneficial effects in NAFLD brought about 
by feeding high-fat diets; reducing the amount of fat accumulation as well as increasing 
P-oxidation in the liver. Of course we cannot eliminate the possibility of other beneficial 
effects. 
Crcatinc-supplemcntion to high-fat fed animals also nonnalized other parameters. 
In particular, elevated plasma glucose and elevated hepatic cholesterol and TBARS were 
nonnalized. The plasma insulin was not significantly higher in the animals on high fat 
diets but the values tended to be higher. However the plasma glucose values indicate that 
insulin sensitivity was improved by creatine supplementation. In addition to lowering 
hepatic triglycerides dietary creatine also decreased hepatic cholesterol levels which is 
what would be expected if VLDL-type particles were accumulating in the liver. Nanna! 
levels of hepatic TSARS indicate that there are less reactive oxygen species in rats fed 
the creatine-supplemented high-fat diet and suggest that there is less lipid peroxidation in 
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this tissue. Thus these side effects of increased accumulation of triglycerides in the liver 
are not seen when creatine is present in the diet. 
6.1.4 Hepatic Zonation in Portacaval Anastomosis 
The paper presented in chapter 5 addresses the question of the fate of perivenous 
hepatocytes when the blood flow from the portal vein is diverted from the liver to 
systemic circulation. Previous work by Butterworth and colleagues (45, 62) suggested 
that there was a selective loss of perivenous hepatocytes based on the dramatic reduction 
ofGS activity observed in this cell population after portacaval anastomosis. The effect on 
GS was also observed in chapter 5 figure 5.1 ; however a significant increase in OAT 
activity was also observed. The OAT protein is known to be colocalized with GS in the 
perivenous cells of hepatic acini (98). Moreover, confocal microscopy confirmed the 
colocalization of GS and OAT as well as the relative fluorescence intensity of the 
antibody stains (figure 5.3) in the rats with portacaval shunts. In addition, the ammonia 
transporter RhBG (figure 5.2), a protein known to be localized in perivenous hepatocytes, 
was unchanged in the livers of rats with portacaval shunts. The findings in chapter five 
are strong evidence against the selective loss of perivenous hepatocytes in favor of 
alterations in gene expression. 
Perhaps the most serious consequence of portacaval anastomosis is 
encephalopathy, with ammonia escaping the high-capacity, low-affinity urea cycle. 
Appreciable reduction in the nom1al "ammonia scavenging" GS causes ammonia levels 
in the plasma to increase. GS is upregulated in the muscle and brain of rats with 
portacaval shunts ( 45) and levels of ammonia and glutamine accumulate in the brain. 
Glutamine has been found to accumulate in the mitochondria of astrocytes causing 
167 
mitochondrial impaim1ent and leading to ultimate dysfunction of cells (4). Glutamine in 
the brain also acts as a precursor for the neurotransmitters glutamate and y-aminobutyric 
acid (GABA) which are agonists of the NMDA and GABA receptors respectively. 
GABA-ergic tone is greater in the brains of patients with hepatic encephalopathy due to 
elevated pregnenolone-derived neurosteroids brought about by elevated ammonia (31). 
NMDA hyperexcitability and increased GABA-ergic tone have both been implicated in 
the progression of neuronal dysfunction in cases of hepatic encephalopathy (55). 
The regulatory mechanisms responsible for the reduction in hepatic GS in 
portacaval shunted rats are unknown. Reduction of hepatic GS activity runs counter to the 
increase in plasma ammonia, exacerbating the hyperammonemia. There arc several 
possible reasons for the down-regulation of hepatic OS in portacaval shunted rats. It has 
been postulated that the proximity of perivenous hcpatocytes to the endothelial cells has 
some regulatory effect on GS expression (58). This has not been proven to be the case in 
the portacaval shunted animals but there is some evidence supporting the notion. 
Another possible factor affecting the expression of GS may be the action of 
glucagon. Pancreatic honnones are found in relatively high concentrations in the portal 
blood. In portacaval anastomosis these honnones wi ll enter the systemic circulation and 
become diluted and therefore the effect on the liver is muted. However, circulating 
concentrations of glucagon are considerably higher in the plasma of rats with portacaval 
anastomosis (11). There is some evidence that glucagon reduces the expression of GS in 
the liver (70) and there is convincing evidence that glucagon action increases the 
expression of OAT in hepatocytes (122). Elevated glucagon would fit very well with the 
observations in chapter 5; however it may not be the only factor at play in tenns of GS 
168 
expression. 
6.2 Limitations and Future Directions 
All scientific techniques have their inherent limitations. Considerations include 
sampling of tissues, post·sampling treatment, assay variability and sensitivity. The types 
of statistical analysis used in analyzing data and the number of subjects (statistical power) 
sampled can also affect the outcome of observed differences and thus can be a limiting. 
In addition, the conclusions that can be drawn from data collected are dictated by what 
questions the techniques are capable of addressing. Thus, I will provide a brief 
explaination of some of the relavant limitations in chapters 2, 3, 4 and 5 in this section. 
The studies on creatine synthesis in the liver and pancreas both involve the 
isolation of cells or groups of cells (acini) from a living tissue. The preparations are 
extensively washed with synthetic medium and incubated under various substrate 
conditions. These studies constitute in vitro experiments which do not precisely match in 
vivo conditions. Therefore we combine in vitro and in vivo data to gain a better 
understanding of the process of creatine synthesis in these two tissues. In vivo techniques 
arc not without their limitations as well. The technique of measuring A-V differences in 
metabolite concentrations across the liver fo r instance are potentially affected by changes 
in blood flow that occur throughout the day. Perhaps a definitive technique for measuring 
creatine synthesis would be to use isotopic tracers to label the substrates of creatine 
synthesis injected into live animals followed by serial blood sampling. However, in order 
to determine tissue specific synthesis of creatine the choice of substrate and isotope 
would have to be tailored to the tissue and the label would have to be injected directly 
into the afferent vessel with collection of efferent blood after first-pass preventing the 
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label from travelling to other tissues where it could be metabolized. Future studies in this 
direction would be beneficial to supp011 or refute the findings in chapters two and three. 
There some complications with dietary supplementation studies as well. Dietary 
creatine supplementation changes the concentration of creatine in the tissues of rats. This 
in itself may cause cell swelling effects and may result in difficulty interpreting 
metabolite concentrations in various tissues. Following this, increased creatine in the 
smooth muscle may have an effect on the tone of blood vessels and thus may vary blood 
flow values. One limitation of the calculations in chapter two is that we did not measure 
blood flow through the liver but instead used average values from the avai lable literature. 
Studies on the effects of creatine on vascular tone and blood flows would be an 
interesting future direction in this area. 
Creatine supplementation in high~ fat diet fed rats prevented NAFLD but the study 
was limited in addressing the mechanism underlying the effect. It is impossible to 
detennine whether the lower lipid levels in the creatine~supplemented rats was due to 
increased export of fat, decreased import of fat, increased oxidation of fat or a 
combination of the either of the three individual possibilities. The phospholipid data is 
limited in that it is impossible to infer flux through PC given a concentration in the liver. 
In addition the observed changes in the expression ofmRNA that were observed may not 
necessarily translate to differences in flux under physiological conditions. Rather they are 
used as evidence to support further research. Further studies in the livers of creatine-
supplemented high~ fat fed rats and their controls should be aimed at measuring oxidation 
of fatty acids, VLDL secretion, and lipid import to determine which factors are 
responsible for the observations in chapter 4. Also, future studies to detem1ine the 
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signaling mechanisms responsible for the changes brought about by creatine 
supplementation are required. 
The study on hepatic zonation addresses the fate of the perivenous hepatocyes but 
fails to address the underlying cellular mechanism controlling GS and OAT. The changes 
to arterial plasma after portacaval shunting are dramatic and widespread. Concentrations 
of many regulatory honnones and metabolites change. Further research directed 
specifically on the regulatory factors affecting GS and OAT are required. Following this, 
intervention with the known regulatory molecules may shed light on what changes are 
taking place in such a complex situation. 
6.4 Closing Remarks 
The quotes given in section 1.3 are descriptive of the nature of scientific research. 
I believe that good research often reveals more questions than answers and so I think it is 
fitting to close this thesis by reviewing some of the interesting questions that this work 
has highlighted. We have put forth evidence that dietary creatine does not govern the 
expression of GAMT in rat liver. What arc the factors regulating GAMT and is there 
some benefit to the constitutive expression of this protein? We were unable to measure 
AGAT activity in the rat liver despite some previous evidence for its expression in this 
tissue. AGAT activity has been measured in other species as well so we may inquire at 
which point this activity was lost in rat liver. 
The effect that creatine supplementation had on lipid accumulation in rat liver of 
rats fed high fat diets was quite dramatic. Creatine supplementation certainly prevented 
many of the negative effects brought about by consuming a high·fat diet. However, the 
mechanism behind the effect remains to be detennined. Does the reduction in 
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methylation demand spare SAM and make it available for methylation of PE? If so, does 
this increase PC synthesis and affect VLOL packaging? In addition, the expression of 
CD36 is altered in the presence of dietary creatine. It remains to be detennined if creatine 
directly affects the expression of this gene or whether there is an indirect mechanism at 
play. 
Finally we deal with the fate of perivenous cells and the zonation of metabolism 
in the liver of rats with portacaval shunts. The opposing regulation of OAT and GS in the 
same population of cells is remarkable. It is clear that the constituents of portal blood 
have major regulatory influence on gene expression in the liver. The portal constituents 
serve to maintain appropriate activities of GS and OAT and hence the character of 
zonation of nitrogen metabolism. The precise regulatory factor(s) affecting hepatic GS 
and OAT expression in portacaval shunted rats remains to be detennined. Finding an 
agent to increase the expression ofGS in the li ver may be beneficial to patients who have 
portacaval shunts. 
Each of the papers presented provides a modest contribution to the field of amino 
acid metabolism in the liver and pancreas. The data and ideas help to advance our 
understanding of creatine biosynthesis and nitrogen metabolism. I hope the questions that 
arise from this work help to stimulate future research in these areas. To paraphrase the 
quotes given in section 1.3: Science is constantly changing and it is important that our 
ideas change in step, as should the questions which fuel the change. This is the nature of 
the study of the physical world: the beautiful, impossible puzzle. 
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